 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 1 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   CLINICAL STUDY PROTOCOL  
 
Study Number V200_10 
Protocol Version FINAL VERSION 1.0: MARCH 2020  
Study Title A Phase 2, Randomized, Stratifie d, Observer-Blind Clinical Stud y 
to Evaluate Safety and Immunogenicity of the MF59 -Adjuvanted 
Quadrivalent Subunit  Inactivated Cell- derived Influenza Vaccine 
(aQIVc) in adults ≥[ADDRESS_757402] Name [CONTACT_282534]59-Adjuvanted Quadrivalent S ubunit Inactivated Cell-derived 
Influenza Vaccine (aQIVc)  
 
Regulatory Agency 
Identifying Number(s)  
IND PTS #[ADDRESS_757403], Maidenhead, [LOCATION_006]   
 
Previous version, if   
applicable  NA 
Date, if applicable NA 
 
 
Property of Seqirus* 
Confidential 
May not be used, divulged, published or otherwise disclosed wit hout the written consent of 
the Sponsor 
*“Seqirus” includes all legal entities under which the company operates
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 2 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757404] of Abbreviations ............................................................... .......................................................... 19 
1 BACKGROUND AND RATIONALE  .............................................................. ......................... 21 
1.1 Background  ............................................................................................................................. 21 
1.2 Rationale  ............................................................................................................................. ....22 
1.3 Potential Risks and Benefits  .............................................................. ..................................... 23 
2 STUDY OBJECTIVES ............................................................................................................... 24 
2.1 Primary Objective  ................................................................................................................... 24 
2.1.1  Primary Immunogenicity Objective  .............................................................. ...................24  
2.2 Secondary Objectives  ............................................................................................................. 24 
2.2.1  Secondary Immunogenicity Objective(s)  .............................................................. ...........24  
2.2.2  Secondary Safety Objectives  ............................................................................................ 25 
2.3 Exploratory Objectives  ........................................................................................................... 25 
3 STUDY DESIGN  .............................................................. ......................................................... 25 
3.1 Overview of Study Design  .............................................................. ....................................... 25 
3.2 Scientific Rationale for Study Design  .............................................................. ......................28  
3.3 Justification for Dose  .............................................................................................................. 28 
3.4 Study Period  .............................................................. ............................................................. 28 
3.5 Blinding Procedures  ............................................................................................................... 28 
3.6 Data Collection  .............................................................. ......................................................... 29 
3.6.1  Data Collected from Subjects  .............................................................. .............................29  
3.6.2  Tools Used for Data Collection  .............................................................. ..........................29  
3.7 Collection of Clinical Specimens  .............................................................. .............................30  
3.8 Stoppi[INVESTIGATOR_007]/Pausing Guidelines  .............................................................. .................................... 31 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 3 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   3.9 Internal Safety Team and Data Monitoring Committee  ......................................................... 32 
3.10  End of Study  .............................................................. ............................................................. 33 
4 SELECTION OF STUDY POPULATION  .............................................................. ................... 33 
4.1 Inclusion Criteria  .............................................................. ...................................................... 33 
4.2 Exclusion Criteria  ................................................................................................................... 34 
4.3 Criteria for Delay of Vaccination  ............................................................................................ 35 
4.4 Criteria for Repeat Vaccination in the Study  .............................................................. ............36  
4.5 Premature Withdrawal from Study  .............................................................. ...........................36  
5 STUDY PROCEDURES  ............................................................................................................ 38 
5.1 Pre-vaccination Procedures: Screening/Randomization  ......................................................... [ADDRESS_757405] -Vaccination Visits  .......................................................................................................... 45 
5.4.1  Follow-up Clinic Visit  .............................................................. ........................................ 45 
5.4.2  Safety Follow-up Calls  .............................................................. ....................................... 45 
5.5 Unscheduled Visits  ................................................................................................................. 46 
5.6 Study Completion Visit ........................................................................................................... 46 
5.6.1  Early Termination Visit  .............................................................. ....................................... 47 
6 TREATMENT OF SUBJECTS  .............................................................. .................................... 48 
6.1 Study Vaccine(s)  .............................................................. ....................................................... 48 
6.2 Non-Study Vaccines  ............................................................................................................... 52 
6.3 Vaccine Preparation and Administration  .............................................................. .................. 52 
6.4 Vaccine Administration Error or Overdose of Vaccine  .......................................................... 53 
6.5 Prior and Concomitant Medications and Vaccines  ................................................................. 54 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 4 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   6.6 Vaccine Supply, Labeling, Storage and Tracking  ...................................................................55  
7 ASSESSMENTS .............................................................. .......................................................... 57 
7.1 Safety Assessments  ................................................................................................................. 57 
7.1.1  Solicited Adverse Events  .............................................................. .................................... 58 
7.1.2  Unsolicited Adverse Events  .............................................................................................. 59 
7.1.3  Evaluation of Adverse Events  .............................................................. .............................60  
7.1.4  Serious Adverse Events  .............................................................. ...................................... 61 
[IP_ADDRESS]  Adverse Events of Special Interest  .............................................................. ...............62  
7.1.5  Methods for Recording Adverse Events and Serious Adverse Events  ............................. 63 
[IP_ADDRESS]  Post-Study Events  .............................................................. ......................................... 64 
7.1.6  Pregnancies  .............................................................. ......................................................... 64 
7.1.7  Safety Laboratory Measurements  .............................................................. .......................64  
7.2 Efficacy Assessment  ............................................................................................................... 64 
7.3 Immunogenicity Assessment  .............................................................. .................................... 65 
8 STATISTICAL CONSIDERATIONS  .............................................................. ........................... 65 
8.1 Endpoints  ................................................................................................................................ 65 
8.1.1  Primary Endpoint(s)  .........................................................................................................65  
[IP_ADDRESS]  Primary Immunogenicity Endpoints  .............................................................. ............66  
[IP_ADDRESS]  Primary Safety Endpoints  .............................................................. .............................66  
8.1.2  Secondary Endpoints  ........................................................................................................66  
[IP_ADDRESS]  Secondary Safety Endpoints  .............................................................. .........................66  
[IP_ADDRESS]  Secondary Immunogenicity Endpoints  ......................................................................67  
8.1.3  Exploratory Endpoints  .............................................................. ........................................ 67 
[IP_ADDRESS]  Exploratory Safety Endpoints .............................................................. ......................67  
[IP_ADDRESS]  Exploratory Immunogenicity Endpoints  ....................................................................67  
8.2 Success Criteria  .............................................................. ........................................................ 68 
8.3 Analysis Sets ............................................................... ............................................................ 68 
8.3.1  All Enrolled Set  ................................................................................................................ 68 
8.3.2  All Exposed Set ................................................................................................................ 68 
8.3.3  Safety Set  .............................................................. ............................................................ 68 
8.3.4  Full Analysis Set (FAS) Immunogenicity  .............................................................. ...........69  
8.3.5  Per Protocol Set (PPS) Immunogenicity .............................................................. ............69  
8.3.6  Other Analysis Sets  ........................................................................................................... 69 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
Document #: FO
RM1-000107830  Ed: 1.0 
Source Document #: SOP-000056619 Page 5 of 91 
Effective Date: See System Metadata  Confidential Print Date (Local): 30-mrt-2020 10:41:00 8.3.7  Subgroups  .............................................................. ........................................................... 69 
8.3.8  Protocol Deviations  .......................................................................................................... 69 
8.4 Statistical Analysis Plan ..........................................................................................................70  
8.4.1  Analysis of Demographic and Baseline Characteristics  ................................................... 70 
8.4.2  Analysis of Primary Objectives  .............................................................. ..........................70  
[IP_ADDRESS]  Analysis of Primary Safety Objectives  ......................................................................70  
[IP_ADDRESS]  Analysis of Primary Immunogenicity Objectives  ...................................................... 70 
[IP_ADDRESS].1. Analysis Sets  ............................................................... .........................................70 
[IP_ADDRESS].2 Statistical Methods ...............................................................................................70 
8.4.3  Analysis of Secondary Objectives  .............................................................. ......................72  
[IP_ADDRESS]  Analysis of Secondary Safety Objectives  ..................................................................72  
[IP_ADDRESS].1  Analysis of Extent of Exposure  .............................................................. ..............72  
[IP_ADDRESS].2  Analysis of Solicited Local, Systemic and Other Adverse Events  .......................72  
[IP_ADDRESS].3  Analysis of Unsolicited Adverse Events  .............................................................. 72 
[IP_ADDRESS].4  Statistical Hypotheses  .............................................................. .............................73  
[IP_ADDRESS].5  Analysis Sets  ........................................................................................................73  
[IP_ADDRESS].6  Statistical Methods  ............................................................................................... 73 
[IP_ADDRESS]  Analysis of Secondary Immunogenicity Objective(s)  ................................................ 74 
[IP_ADDRESS].1  Statistical Hypotheses  .............................................................. .............................74  
[IP_ADDRESS].2  Analysis Sets  ........................................................................................................74  
[IP_ADDRESS].3  Statistical Methods  ............................................................................................... 74 
8.4.4  Analysis of Other Objectives  ............................................................................................ 74 
[IP_ADDRESS]  Analysis of Other Safety Objectives  .............................................................. ............74  
[IP_ADDRESS]  Analysis of Other Immunogenicity Objectives  .......................................................... 74 
8.5 Sample Size and Power Considerations of Primary Objectives  ............................................. 75 
8.6 Interim Analysis  .............................................................. ........................................................ 75 
9 SOURCE DOCUMENTATION, STUDY MONITORING, AND AUDITING ......................... 76 
9.1 Source Documentation  ........................................................................................................... 76 
9.2 Study Monitoring, Auditing and Source Data Verification  .................................................... 77 
10 DATA MANAGEMENT  ............................................................................................................ 78 
10.1  Data Entry and Management  .............................................................. .................................... 78 
10.2  Data Clarification ................................................................................................................... 78 
10.3  Data Protection  .............................................................. ......................................................... 78 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 6 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757406] RETENTION  ............................................................................................................. 79 
12 USE OF INFORMATION AND PUBLICATION  ..................................................................... 79 
13 ETHICAL CONSIDERATIONS  .............................................................. .................................. 80 
13.1  Regulatory and Ethical Compliance  .............................................................. .........................80  
13.2  Informed Consent Procedures  ................................................................................................ 80 
13.3  Responsibilities of the Investigator and IRB/IEC  ..................................................................[ADDRESS_757407]  .............................................................. ...................................................... 83 
APPENDIX 1 – HAK SCORE  ......................................................................................................... 86 
APPENDIX 2 – LIST OF ADVERSE EVENTS OF SPECIAL INTEREST  ................................... 87 
APPENDIX 3 – SPONSOR AND INVESTIGATOR SIGNATURE [CONTACT_118585]  .................................. 90 
  
  
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 7 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757408] of Tables 
Table 0-1: Time and Event Schedule  .............................................................. .................................. 16 
Table 3-1: Pause Rules for Planned IST Review  .............................................................. ................ 32 
Table 5-1: Study Procedures  ............................................................................................................. 39 
Table 6-1: aQIVc Vaccine Composition  .............................................................. ............................. 49 
Table 6-2: aQIV Vaccine Composition  .............................................................. ............................... 50 
Table 6-3: QIVc Vaccine Composition ............................................................................................. 51 
Table 6-4: QIVr Vaccine Composition  .............................................................. ................................ 52 
Table 7-1: Severity Grading for Solicited Local and Systemic Ad verse Events  .............................. 58 
Table 8-1: Detectable GMT ratios  .............................................................. ...................................... [ADDRESS_757409] of Figures  
Figure  3-1 Overview of the Study  .............................................................. ...................................... 26 
 
 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 8 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   PROTOCOL SYNOPSIS  
Name [CONTACT_790]:  
Seqirus  
 Protocol number:  
V200_10  Generic name [CONTACT_577339]:  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Cell -derived Influenza Vaccine 
(aQIVc)  
Quadrivalent Sub unit Inactivated Cell -
derived Influenza Vaccine (QIVc)  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Egg -derived Influenza Vaccine 
(aQIV)  
Recombinant Quadrivalent influenza 
vaccine (QIVr)  
Title of Study:  
A Phase 2, Randomized, Stratified, Observer -blind Clinical Study to Evaluate Safety 
and Immunogenicity of the MF59 -adjuvanted Quadrivalent Inactivated Subunit Cell-
derived Influenza Vaccine (aQIVc) in Adults ≥50 Years of Age.  
Study Period:  Approximately 6 months 
for each study participant.  Clinical Phase: Phase 2 
Background and Rationale:  
Vaccination is the primary method f or preventing influenza and its severe complications. 
The efficacy of the conventional influenza vaccines in the adul t population is 
demonstrated to be high. In contrast, the efficacy in elderly i ndividuals is significantly 
lower due to the aging of the immune system (i.e. immunosenesce nce) and underlying 
medical conditions that can both increase the risk of influenza  complications as well as 
interfere with immune responses ( Sasaki et al. 2011 ). In view of the limitations of 
conventional influenza vaccines in older adults, there continue s to be an unmet need for 
a new generation of influenza vaccines that provides more consi stent and broader 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 9 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757410] all seasona l virus subtypes and variants ( Wong and Webby 2013 ; Reber 
et al. 2012 ). 
The MF59 -Adjuvanted Quadrivalent Subunit Inactivated Cell- derived Influenza Vaccine 
(aQIVc) o ffers important advantages over conventional influenza vaccines . aQIVc 
combines the benefits of both cell -based and adjuvanted technologies to meet the unmet 
need of influenza in older adults. The cell -derived antigen provides a better match to 
circulating  strains, therefore addressing mismatch due to egg adaptation ( Hedge 2015;  
Lambert et al . 2010 ). The effect of inclusion of MF59 adjuvant to the vaccine is e xpected 
to enable increased magnitude of immune response by [CONTACT_577260]; increased breadth of immune respon se by [CONTACT_577261]; and increased duration of immune response with higher antibody 
response at 6 months after vaccination which is important in ca se of prolonged influenza 
seasons and/or late -season outbreaks ( Frey et al. 2014 ). 
The aim of this study is to perform a n evaluation of the immunogenicity and safety of the 
MF59 -adjuvanted Quadrivalent cell- based vaccine versus other influenza vaccines, such 
as the non -adjuvanted Quadrivalent cell-based influenza vaccine, the MF59 -adjuvanted 
Quadrivalent egg -based vaccine, and the recombinant Quadrivalent vaccine. 
Immunogenicity and safety will  be assessed in the overall stu dy population (adults ≥50 
years of age) and for the age subgroups 50-64 years and ≥65 years in order to assess the 
benefit/risk profile of aQIVc in each age population for this v accine.  
Disclosure Statement : This is a parallel-group treatment study with f our arms that is 
observer -blinded. 
Study Objectives:   
Primary Objectives:   
Primary Immunogenicity Objective :  
1. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV , and QIVr 
comparator vaccines as measured by [CONTACT_35318] (HI) assay* using 
cell-derived target viruses at 28 days after vaccination, in subjects 50- 64 and ≥65 
years of age and overall (adults ≥50 years of age).  
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 10 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   * In case of lack of agglutination for a specific strain , immunogenicity for that strain will be assessed as 
measured by [CONTACT_577262] (MN) assay as an acceptable alternative. 
Secondary Objectives:   
Secondary Immunogenicity Objectives:  
1. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV , and 
QIVr comparator vaccines as measured by [CONTACT_387191]* using cell-derived  target 
viruses at 180 days after vaccination, in subjects 50-64 and ≥6 5 years of age and 
overall.  
2. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV , and 
QIVr comparator vaccines as measured by [CONTACT_577263]-derived  target 
viruses at 28 and 180 days after vaccination, in subjects 50-64  and ≥65 years of 
age and overall.  
* In case of lack of agglutination for a specific strain , immunogenicity for that strain will be assessed as 
measured by [CONTACT_577264].  
Seco ndary Safety Objectives:  
1. To assess the reactogenicity of aQIVc as compared to QIVc, aQIV , and QIVr in 
subjects 50-64 and ≥65 years of age and overall for 7 days afte r vaccination.  
2. To assess the safety of study vaccines in subjects 50-64 and ≥6 5 years of a ge and 
overall for 180 days after vaccination.  
Exploratory Objectives:   
Further details on exploratory objectives are provided in Section 2.3, Exploratory 
Objectives.  
Primary and Secondary Endpoints:  
A list of p rimary and secondary endpoints is provided in Section 8.1, Endpoints .  
Study Design:  
Experimental design: This is a Phase 2, randomized, stratified, controlled, observer -blind, 
multi -center study in approximately 480 male and female adults aged 50 years and older 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 11 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757411] co-morbidities which increase their ris k of complications from 
influenza infection.  
Duration of the study:  The study duration is approximately [ADDRESS_757412]. The 
study will be condu cted in one single season.  
Vaccination schedule:  Single vaccination (Day 1).  
Investigational Vaccine:  aQIVc.  
Comparator Vaccines : QIVc, aQIV and QIVr.  
Treatment groups:  
Enrolled subjects will be randomized to one of the four treatme nt groups in a 1:1:1:1 ratio.  
1. aQIVc group: approximately 120 subjects receiving one dose of a QIVc on Day 1. 
2. QIVc group: approximately 120 subjects receiving one dose of QI Vc on Day 1. 
3. aQIV group: approximately 120 subjects receiving one dose of aQIV on Day 1. 
4. QIVr group: approxim ately 120 subjects receiving one dose of QIVr on Day 1. 
Randomization:  an Interactive Response Technology (IRT) will be used in the study with 
stratification factors for age (≥50 to 64 and ≥65 years, with about 50% of the subjects 50-
64 years of age and ab out 50% of the subjects ≥65 years of age for each treatment group)  
and history of any influenza vaccination within 3 previous influenza seasons (yes/no). 
Approximately 40% of subjects i n each age subgroup for each tre atment group should not 
have been vacc inated with an influenza vaccine within the 3 previous influenza seasons.   
Blinding:  Observer-blind study.  
Blood sample schedule:  Three blood samples will be collected from all subjects on Day  1, 
Day 29 and Day 181.  
Data collection:  electronic Case Reporting Form (eCRF).  
Study periods:  The study has a treatment period and a follow- up period. Treatment period 
(Day 1 to Day 29) and the Follow -up Period (Day 30 to Day 181).  
Study clinic visits  Three clinic visits for each subject on Day 1, Day 29 and Day 181.  
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 12 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Safety phone call: Two safety phone calls (Day 7 and Day 91) will be conducted to collect 
any unsolicited Adverse Events (AEs) (on Day 7 only), Medically Attended Adverse 
Events (MAAEs) , AEs leading to withdrawal, Serious Adverse Events (SAEs) and 
Adverse Event of Special Interest (AESIs), related medications and any vaccinations.    
Reactogenicity data collection:  Solicited AEs will be recorded daily for 7 consecutive 
days (or longer if the events are not resolved) following vacci nation (Day 1 to Day 7) 
using a Subject eDiary to be completed by [CONTACT_423].  
Safety data collection: Unsolicited AEs will be collected for [ADDRESS_757413] during the 
clinic visits and safety phone calls and by [CONTACT_577265]. Subjects 
will be instructed to call the site in the event of any AE whic h they perceive as being of 
concern dur ing the entire study period.  
Serological assays :  
x HI assay for homologous vaccine strains, using cell-derived target virus, will be 
performed in all subjects on se rum samples collected on Days 1,  29 and 181.  
x MN assay for homologous vaccine strains, using cell-derived  target virus, will be 
performed in all subjects on se rum samples collected on Days 1,  29 and 181.  
Number of Subjects planned:   
Approximately [ADDRESS_757414] Characteristics:   
This study will enroll male and fe male adults aged [ADDRESS_757415] of inclusion and exclusi on criteria are included in protocol Section 4, Selection 
of Study Population .  
Study Procedures:   
Written informed consent must be obtained prior to performing a ny study -related 
procedures.  
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 13 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   On Day 1, screening evaluations will be performed and will incl ude a review of relevant 
medical history, physical examination, including body temperature and an eligibility 
assessment.  
All eligible subjects will then be randomized and subsequently receive a single dose of 
0.5 mL  of study vaccine to which they were assigned. Blood samples for  serology testing 
will be collected on Day 1 (prior to vaccination), Day 29 and D ay 181. Subjects will be 
followed up for safety for 180 days after vaccination.  
Further details on the study pr ocedures are presented at the end of the synopsis in Table 
0-1 and in Section 5, Study Procedures . 
Study Vaccines:   
Regardless of the type of vaccine assigned in the trial, subjects will receive a 0.5 mL dose, 
administered intramuscularly into the deltoid muscle, preferabl y in the non -dominant 
arm. Haemagglutinin (HA) antigens are derived from the four influenz a virus strains 
(A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended b y the WHO 
(World Health Organization) for quadrivalent vaccines for the r espective season.  
 
 
Investigational Vaccine  
x Quadrivalent Subunit Inactivated Cell- derived Influenza Vaccine, which includes 
MF59 adjuvant.  
Comparator vaccines:  
x Non-adjuvanted Quadrivalent Subunit Inactivated Cell- derived Influenza Vaccine 
(QIVc).  
x Quadrivalent Subunit Inactivated Egg-derived Influenza Vacci ne, which includes 
MF59 adjuvant (aQIV).  
x Recombinant Quadrivalent Influenza Vaccine (QIVr).  
Statistical Analyses:  
The primary analysis will be conducted on the immunogenicity an d safety data collected 
up to Day 29. Exploratory comparisons of HI Geometric Mean Tite r (GMTs) and MN 

 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 14 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   GMTs between treatment groups will be performed through the com putation of the two-
sided 95% confidence interval (CI) of the vaccine group ratio o f GMTs:  
GMTs aQIVc / GMTs comparator groups  
To estimate the GMT ratio (adjust ed analysis), a general linear  model (GLM) will be fitted 
on log -transformed (base ten) post- vaccination HI titer as the outcome variable and terms 
for covariates: vaccine treatment, log [ADDRESS_757416] square 
means (on the log scale) will be produced with 95% confidence l imits. The estimated 
difference and the confi dence limits will be back-transformed to obtain an adjusted GMT 
ratio with 95% confidence limits. Each of the four strains will be an alyzed separately.  
The difference in seroconversion rates (SCRs) or percentage of subjects with HI titer 
≥1:40 will be presented with 95% CIs using the Miettinen and Nu rminen method without 
and with adjustment for the age stratum.   Each of the four strains will be analyzed 
separately.   
Additionally, exploratory comparisons between groups will be pe rformed through the 
computation of the two -sided 95% CI for the difference in the percentages between aQIVc 
vaccine and comparator groups.  
Statistical Considerations for  Sample Size Calculations:  
A total of 480 subjects (inclu ding a 10% drop- out rate) will be enrolled in this study and 
are to be randomized in a 1:1:1:1 ratio to one of the four vacc ine groups. Approximately 
one hundred twenty subjects will be enrolled in each vaccine gr oup. More details on the 
sample size calcul ation are provided in Section 8.5 .  
Interim Analysis:   
An interim analysis is no t planned for this study.  
Internal Safety Team and Da ta Monitoring Committee:  
Because the investigational vaccine (aQIVc) has never been admi nistered to humans, 
additional safety precautions have been incorporated in this st udy. An internal safety team 
(IST), independent from the clinical study, will review the saf ety information  as soon as 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830  Ed: 1.0  
Source Document #: SOP-000056619   Page 15 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757417] 40 and 120 enrolled 
subjects . In addition, an independent Data  Monitoring Committee (DMC) will be used 
for the study. See Section 3.8, Stoppi[INVESTIGATOR_007]/Pausing Guidelines and Section 3.9, Internal 
Safety Team and Data Monitoring Committee  for further details.  
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619   Page 16 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Table 0-1: Time and Event Schedule 
 Visit Type Clinic Visit Safety Phone 
Call Clinic Visit Safety Phone 
Call Clinic Visit 
Study Day 1 7 29 91 181 
Visit Window (Days) n/a -1/+3 day -7/+3 days +/-7 days +/-7 days 
 Visit Number 1 2 3 4 5 
Study Event References      
Study Treatment       
Vaccination  Section 5.2  X     
Screening and Safety       
Informed Consent   Section 5.1.1 Xa     
Medical Historyb Section 5.1.2 X     
Pregnancy testc Section 5.1.2   X     
Physical Exam Section 5.1.2   X     
Targeted Physical Examd Section 5.4.1 X  X  X 
Measuring body temperature Section 5.1.2 X     
Exclusion/Inclusion Criteria  Section [ADDRESS_757418] eDiary  Section 5.3   X     
Review of eDiary data and 
compliance Section 3.6.2 Ongoing during eDiary use    
Assess unsolicited AEs Section 7.1.2 X X X   
Assess SAEs Section 7.1.4 X X X X X 
 
Protocol Number: V200_10  
Product Name: [CONTACT_577338]: Final Version 1.0, Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619   Page 17 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                    Visit Type Clinic Visit Safety Phone 
Call Clinic Visit Safety Phone 
Call Clinic Visit 
Study Day 1 7 29 91 181 
Visit Window (Days) n/a -1/+3 day -7/+3 days +/-7 days +/-7 days 
 Visit Number 1 2 3 4 5 
Study Event References      
Assess for AEs leading to withdrawal, 
medically attended AEs and AESIs Section [IP_ADDRESS]  X X X X X 
Assess relevant medications and 
vaccinations Section 6.5   X X X X X 
Immunogenicity       
Serology blood draw Section 5.1.5 X  X  X 
Study Completion/termination Section 5.6      Xe 
Notes: a Consent form(s) should be signed prior to performing any proced ures. The informed consent process may be conducted earlier, bu t within [ADDRESS_757419]. e Subjects who terminate the study early will be requested to co mplete all safety-related Study Completion procedures. Abbrevia tions: AE = adverse event; 
AESI = adverse event of special interest; n/a = not applicable;  SAE = serious adverse event. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 18 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757420] that has not been vaccinated within 3 previous 
influenza seasons.  
Qualified healthcare 
professional  Any licensed health care professional who is permitted by 
[CONTACT_577266](s) and who is identified within the site signature [CONTACT_1629] d 
delegation log.
 
Trained healthcare 
professionals  Any health care professional who is permitted by [CONTACT_274424], trained to perform delegated tasks, is trained on the s tudy 
procedure(s) and who is identified within the site signature [CONTACT_1629] d 
delegation log.  
Treatment period  
 
 The treatment period begins at the time of vaccination and ends  
[ADDRESS_757421] occurred after hysterectomy, after bilateral oophorectomy, or iatrogenic ablation of ovarian function
. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 19 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757422] Research Organization  
CSR   Clinical Study Report  
CTAB   cetyltrimethylammonium bromide  
DMC   Data Monitoring Commitee  
DNA   deoxyribonucleic acid  
eCRF   electronic Case Report Form  
eDiaries  electronic Diaries  
EC  Ethics Committee (paired with Institutional Review Board)  
EDC   Electronic Data Capture  
EMA   European Medicines Agency  
FAS  Full Analysis Set    
FDA   Food and Drug Administration   
GCP   Good Clinical Practices  
GDPR   General Data Protection Regulation  
GMFI  geometric mean fold increase  
GMR   geometric mean ratio  
GMT   geometric mean titer  
HA  hemagglutinin  
HI  hema gg
lutination inhibition  
HIPAA  Health Insurance Portability and Accountability Act    
ICF  Informed Consent Form  
ICH  International Committee on Harmonization    
IEC  Independent Ethics Committee    
IM  intramuscular  
IRB  Institutional Review Board  
IRT  Interactive Response Technology  
IST  Internal Safety Team 
IV  Intravenous  
LL  lower limit  
LLOQ   Lower Limit of Quantitation  
MAAEs Medically attended Adverse Events  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 20 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757423] deviation  
SCR   seroconversion rate  
SDA   Source Data Agreement  
SH  Southern Hemisphere    
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
US  [LOCATION_002]  
VE  Vaccine efficacy  
WHO   World Health Organization  
 
 
 
 
 
 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 21 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   1 BACKGROUND AND RATIONALE  
1.1 Background  
Influenza is an infectious acute respi[INVESTIGATOR_577242], such as fever, cough, sore throat and rh initis ( Temte and Prunuske 2010 ). 
Influenza occurs in annual epi[INVESTIGATOR_577243]  (NH) and southern hemisphere (SH) 
generally affecting individuals during the winter months in tem perate climates. In tropi[INVESTIGATOR_227910], 
it can occur all year round. 
Influenza in humans can be caused by [CONTACT_577267] A, B, and C, of which type A and B 
viruses are most clinically relevant. Type A viruses are associ ated with both annual epi[INVESTIGATOR_577244], and B viruses contribute to annual epi[INVESTIGATOR_7509] ( WHO 2018 ). The type A viruses are further 
divided into different subtypes, of which the A/H3N2 and A/H1N1  viruses are the most clinically 
relevant for annual influenza disease burden. For influenza B, only a single type is known to exist, 
but [ADDRESS_757424] genetic lineages are identified: Yamagata and Vi ctoria ( CDC 2019a ). All influenza 
viruses experience some form of antigenic drift, but it is most pronounced in the influenza A virus 
for which new circulating variants are frequently observed over the influenza season. Such evolution 
of the influenza virus influences the host specificity and path ogenicity of these viruses which can 
differ geographically, from season to season and within a seaso n. 
Influenza is an acute and highly contagious viral infection wit h global circulation. Every year across 
the globe, there are an estimated 1 billion cases of influenza disease, of which 3 to 5 million are 
severe cases, resulting in 290 000 to 650 000 influenza-related  respi[INVESTIGATOR_577245] ( WHO 2018 ; 
Iuliano et al. 2018 ). In the [LOCATION_002] (US), influenza-related hospi[INVESTIGATOR_230225] 15 seasons 
was estimated to be 309 per 100 000 in individuals 65 years and older ( Zhou et al. 2012 ). Although 
the rate of hospi[INVESTIGATOR_577246] [ADDRESS_757425] number of influ enza illnesses and medical visits is 
reported for the 50 to 64 years of age cohort, which indicates also a high burden of disease in this 
age group ( CDC 2019b ). 
Vaccination is the primary method for preventing influenza and its severe complications. The efficacy 
of the conventional influenza vaccines in the adult population is demonstrated to be high ( Roshini 
and Miller 2019). In contrast, the efficacy in elderly individuals is signific antly lower due to the aging 
of the immune system (ie immunosenescence) and underlying medical conditions that can both 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 22 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   increase the risk of influenza co mplications as well as interfe re with immune responses ( Sasaki et al. 
2011).  
In view of the limitations of conventional influenza vaccines i n older adults, there continues to be an 
unmet need for a new generation of influenza vaccines that prov ides more consistent and broader 
coverage against all seasonal virus subtypes and variants (Wong and Webby 2013 ; Reber et al. 2012 ). 
One approach to overcoming immunosenescence is to enhance the immune response by [CONTACT_577268], such as the squalene and water emulsion adjuvan t, MF59. The addition of MF59 
increases antigen uptake, macrophage recruitment, macrophage mi gration, and the spectrum of 
antibody recognition of HA epi[INVESTIGATOR_322] (Calabro et al. 2011 ; O’Hagan et al. 2012 ). Thus, when added 
to influenza vaccines, MF59 increases vaccine immunogenicity ag ainst both homologous and 
heterologous strains. Fluad®, Seqirus’s trivalent seasonal influenza egg -based vaccine adjuvanted 
with MF59, has been licensed for use in Europe since 1997 and i n the US since 2015. It has been 
shown to generate significantly higher geometric mean hemagglut ination inhibition (HI) titers and 
rates of seroconversion than a nonadjuvanted trivalent influenz a vaccine comparator in elderly 
subjects ( Frey et al. 2014 ). 
The investigational vaccine in this study, MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-
derived Influenza Vaccine (aQIVc), combines benefits of both ce ll-based, and adjuvanted 
technologies to meet the unmet need of influenza in older adults. The cell-derived antigen provides 
a better match to circulating strains, therefore addressing mis match due to egg adaptation ( Hedge 
2015; Lambert et al. 2010 ). The effect of inclusion of MF59 adjuvant to the vaccine is e xpected to 
enable increased magnitude of immune response by [CONTACT_577269]; increased breadth of immune response by [CONTACT_577270], and increased duration of immune response with higher antibody response at 6 months after vaccination 
which is important in case of prolonged influenza seasons and/o r late-season outbreaks.  
1.2 Rationale  
The purpose of this study is to perform an evaluation of the im munogenicity and safety of the MF59-
adjuvanted Quadrivalent cell-based vaccine (aQIVc) versus other  influenza vaccines, such as the 
non-adjuvated Quadrivalent cell-based influenza vaccine (QIVc), the MF59-adjuvanted Quadrivalent egg-based vaccine ( aQIV)  and the Quadrivalent rec ombinant influenza vaccine (QIVr). 
Immunogenicity and safety will be assessed in the overall study  population (adults ≥50 years of age 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 23 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   and for the age subgroups 50-64 years and ≥65 years in order to  assess the benefit/risk profile in each 
age population for this vaccine.  
1.3 Potential Risks and Benefits  
Subjects will be exposed to aQIVc or QIVc or aQIV or QIVr vacci nes. 
As with all injectable vaccines,  immediate systemic allergic re actions to vaccination can occur. The 
reactions for anaphylaxis are sporadic and estimated to be 1.3 per million vaccine doses administered 
for all vaccines ( McNeil 2019 ). As a precautionary measure, all subjects will remain under 
observation at the study site for at least 30 minutes after vac cination. Vasovagal syncope (fainting) 
can occur before or after any vaccination, is usually triggered  by [CONTACT_577271]. Therefo re, it is important that standard 
precautions and procedures be followed to avoid injury from fainting. Intramuscular vaccination 
commonly precipi[INVESTIGATOR_14263] a transient and self-limiting local infla mmatory reaction. This typi[INVESTIGATOR_577247], erythema (redness), or swelling ( hardness). 
aQIVc is expected to provide benefit over existing conventional influenza vaccines in older adults 
by [CONTACT_577272]59 adjuvant and the use of antig ens produced in cell culture that more 
closely resemble the wild-type strains (Hedge 2015 ; Lambert et al. 2010 ). With the addition of MF59, 
aQIVc is expected to provide a robust immune response similar t o the immune response elicited after 
vaccination with aQIV in older adults ( Frey et al. 2014 ). 
Overall, the clinical safety experience with aQIV and QIVc in o lder adults, in conjunction with data 
from the repeat dose  aQIVc toxicology study are sufficient to support the initiation of a Phase 2 
safety and immunogenicity study in adults 50 years and older. I n the repeat-dose toxicity study, three 
doses of aQIVc, containing  HA/dose, were administered by [CONTACT_577273] 3-week int ervals. The vaccine was immunog enic and there was no evidence of 
local or systemic toxicity. The most common local and systemic reactions observed in the adjuvanted 
egg-based comparator vaccine (aQIV) in older adults were inject ion site pain, headache, and fatigue. 
Most reactions were reported as mild or moderate in intensity. The most common local and systemic 
reactions associated with administration of the QIVc comparator  vaccine in older adults included 
injection site pain, erythema, induration, headache, fatigue, a nd myalgia. Most reactions were 
reported as mild or moderate in intensity. For the aQIVc vaccin e, similar local and systemic reactions 
are to be expected as for the aQIV and QIVc vaccines. 

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 24 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Because the investigational vaccine (aQIVc) has never been admi nistered to humans, additional 
safety precautions have been incorporated in this study (see Section 3.8, Stoppi[INVESTIGATOR_007]/Pausing 
Guidelines ). 
Please refer to the current Investigator’s Brochure (IB) for aQ IVc for a summary of potential risks 
and benefits of aQIVc; to the Product Information for QIVc and QIVr for a summary of potential 
risks and benefits of QIVc and QIVr respectively, and to the cu rrent IB for aQIV for information 
regarding the potential risks and benefits of aQIV .  
2 STUDY OBJECTIVES  
2.1 Primary Objective  
2.1.1 Primary Immunogenicity Objective  
1. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV, and QIVr 
comparator vaccines as measured by [CONTACT_387191]* using cell-derived  target viruses at 28 days 
after vaccination, in subjects 50-64 and ≥65 years of age and o verall (adults ≥50 years).  
* In case of lack of agglutination for a specific strain using HI assay, immunogenic ity for that strain will be assessed as 
measured by [CONTACT_363947] (MN)  assay as an acceptable alternative. 
For primary endpoints, refer to Section 8.1.1, Primary Endpoints . 
2.2 Secondary Objectives  
2.2.1 Secondary Immunogenicity Objective(s) 
1. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV, and QIVr 
comparator vaccines as measured by [CONTACT_387191]* using cell-derived target viruses at 180 days 
after vaccination, in subjects 50-64 and ≥65 years of age and o verall.  
2. To assess the immunogenicity of aQIVc in comparison with the QI Vc, aQIV, and QIVr 
comparator vaccines as measured by [CONTACT_577263]-derived target viruses at 28 and 
180 days after vaccination, in subjects 50-64 and ≥65 years of age and overall.  
* In case of lack of agglutination for a specific strain using HI assay, immunogenic ity for that strain will be assessed as 
measured by [CONTACT_577274]. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 25 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   For secondary immunogenicity endpoints, refer to Section [IP_ADDRESS], Secondary Immunogenicity 
Endpoints . 
2.2.2 Secondary Safety Objectives 
1. To assess the reactogenicity of aQIVc as compared to QIVc, aQIV , and QIVr in subjects 50-
64 and ≥65 years of age and overall for 7 days after vaccination.  
2. To assess the safety of study vaccines in subjects 50-64 and ≥6 5 years of age and overall for 
180 days after vaccination.  
For secondary safety endpoints, refer to Section [IP_ADDRESS], Secondary Safety Endpoints . 
2.3 Exploratory Objectives 
1. The immunogenicity of aQIVc in comparison with the QIVc, aQIV a nd QIVr comparator 
vaccines as measured by [CONTACT_577275]-derived target viruses at 28 days 
after vaccination, in subjects 50-64 and ≥65 years of age and o verall.  
2. Additional exploratory immunogenicity analyses may be conducted  to further characterize 
the immune response of aQIVc.  
For exploratory endpoints, refer to Section 8.1.3, Exploratory Endpoints . 
The results of these exploratory analyses may be presented in a n addendum to the Clinical Study 
Report (CSR). 
3 STUDY DESIGN 
3.1 Overview of Study Design 
Experimental design: Phase 2, ra ndomized, stratified, controlle d, observer-blind, multi-center study 
in approximately [ADDRESS_757426] co-
morbidities which increase their risk of complications from influenza infection. An overview of the study design presented in Figure  3-1. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 26 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Figure  3-1: Overview of the Study   
 
 
Notes: aDuring this call/visit, non-serious unsolicited adverse events will not be collected. Abbreviations: aQIVc= MF59-adjuvanted 
Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine . QIVc= Quadrivalent subunit inactivated cell-derived influenza  
vaccine. aQIV= MF59-adjuvanted Quadrivalent Subunit Inactivated  egg-derived Influenza Vaccine. QIVr= Recombinant 
Quadrivalent  influenza vaccine.  
Duration of the study: The study duration is approximately [ADDRESS_757427]. The study will 
be conducted in one single season.  
Vaccination schedule: Single intramuscular injection on Day 1.  
Investigational Vaccine: aQIVc.  
Comparator Vaccines: QIVc, aQIV and QIVr.  
Treatment groups: 
Enrolled subjects will be randomized to one of the four treatme nt groups in a 1:1:1:1 ratio. 
1. aQIVc group: approximately 120 subjects receiving one dose of a QIVc on Day 1.  
2. QIVc group: approximately 120 subjects receiving one dose of QI Vc on Day 1.  
3. aQIV group: approximately 120 sub jects receiving one dose of aQ IV on Day 1.  
4. QIVr group: approximately 120 subjects receiving one dose of QI Vr on Day 1.  
Randomization: an Interactive Response Technology (IRT) will be  used in the study with 
stratification factors for age (≥50 to 64 and ≥65 years, with a bout 50% of the subjects 50-64 years of aQIVc  (120 subjects )
QIVc (120 subjects)
aQIV (120 subjects )
QIVr (120 subjects)
Day 1  
Clinic Visit 
Visit 1 
 Day 7 
Safety phone call 
Visit 2 Day 29 
Clinic Visit 
Visit 3  Day 91 
Safety phone call 
Visit 4  Day 181  
Clinic Visit 
Visit 5  
Randomization 
 Assessment of safety  Assessment of 
safety/ review of 
reactogenicity data Assessment of safetya  Assessment of 
safetya 
Serology blood draw  Serology blood draw  Serology blood 
draw 
Vaccination    Study Completion Randomization 
(1:1:1:1) 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 27 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   age and about 50% of the subjects ≥65 years of age for each tre atment group) and history of any 
influenza vaccination within 3 previous influenza seasons (yes/ no). Approximately 40% of subjects 
in each age subgroup for each treatment group should not have b een vaccinated with an influenza 
vaccine within the 3 previous influenza seasons.  
Blinding: Observer-blind study.  
Blood sample schedule: Three blood samples will be collected fr om all subjects on Day 1, Day 29 
and Day 181.  
Data collection: electronic Case Reporting Form (eCRF).  
Study periods: The study has a treatment period and a follow-up period. Treatment period (Day 1 to 
Day 29) and Follow-up Period (Day 30 to Day 181)  
Study clinic visits: Three clinic visits for each subject on Da y 1, Day 29 and Day 181.  
Safety phone call: Two safety phone calls (Day 7 and Day 91) wi ll be conducted to collect any 
unsolicited Adverse Events (AEs) (on Day 7 only), MAAE, AEs lea ding to withdrawal, Serious 
Adverse Events (SAEs) and AESIs, related medications and any va ccinations.    
Reactogenicity data collection: Solicited AEs will be recorded daily for 7 consecutive days (or longer 
if the events are not resolved) following vaccination (Day 1 to  Day 7) using a Subject eDiary as 
completed by [CONTACT_423].  
Safety data collection: Unsolicited AEs will be collected for [ADDRESS_757428] during the clinic visits and safety phone calls 
and by [CONTACT_299891]. Subjects will be in structed to call the site in the event of 
any AE which they perceive as being of concern during the entire study period.  
Serological assays:  
x HI assay for homologous vaccine strains, using cell-derived tar get virus, will be performed 
in all subjects on serum samples collected on Days 1, 29 and 18 1.  
x MN assay for homologous vaccine strains, using cell-derived tar get virus, will be performed 
in all subjects on serum samples collected on Days 1, 29 and 18 1. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 28 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757429] of the 
addition of MF59 in aQIVc in terms of immunogenicity.  
aQIV and QIVr are chosen as comparators to assess the immunogenicity and safety of aQIVc versus 
'enhanced' influenza vaccines that are recommended for older ad ults in some regions.  
3.3 Justification for Dose  
The selected dose and formulation of aQIVc (  of HA of each viral strain and  of MF59 
per dose) is expected to be well tolerated and to induce a high er immune response compared to 
conventional influenza vaccines.  
 Safety pro files of aQIV and QIVc have been 
well characterized in both younger and older adults. No safety concerns were observed from the aQIV 
and QIVc clinical studies.  
3.[ADDRESS_757430] study visit.  
3.5 Blinding Procedures 
The study is designed as an observer-blind study. Observer-blin d means that during the course of the 
study designated and trained unblinded nurse(s), physician(s), or other qualified health care 
professional(s) will be responsible for administering the study  vaccines to the subjects. They will be 
instructed not to reveal the identity of the study vaccines eit her to the subject or to the investigative 
site personnel (i.e., investigator and study nurse) involved in  the conduct of the trial, except in an 
emergency if unblinding in IRT is not possible. Vaccine adminis tration should be shielded from the 
subject and blinded study personnel. The unblinded personnel sh ould not be involved in data 
collection, data entry or data review such as safety assessment s and/or collect study data after the 
vaccinations. Study vaccines will be assigned through an IRT sy stem.  

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 29 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757431] over the  duration of their study participation:  
x Demographic Information. 
x Medical History, including existing comorbidities. 
x Influenza vaccination history. 
x Physical examination including temperature, height, and weight.  
x Reactogenicity: Solicited AEs for 7 consecutive days (or longer  if the events are not resolved) 
following vaccination (Day 1 through Day 7). 
x Unsolicited AEs for 28 days following vaccination (Day 1 throug h Day 29). 
x SAEs, MAAEs, AEs leading to withdrawal from the study, AESIs as collected from Day 1 
through Day 181. 
x Concomitant Medications/vaccinations (as defined in  Section 6.5 ). 
x Reason for early study termination. 
 
All data collected must only be identified using the Sponsor Su bject ID, as described in Section 5.1.4,  
Randomization.  
3.6.[ADDRESS_757432] eDiary and collected on Ca se Report Forms (eCRFs).  
Subject eDiary  
Electronic Diaries (eDiaries), hereafter referred to as Subject eDiaries, will be the only source 
document allowed for solicited local and systemic adverse event s (including body temperature 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 30 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   measurements), starting after the initial [ADDRESS_757433]-vaccination period at the clinic, and 
continuing for 7 consecutive days (or longer if the events are not resolved). Refer to the user’s manual 
for further details.   
The Investigator or delegated, qualified health care staff should review the Subject’s eDiary data and 
monitor the Subject’s eDiary  status for compliance on an ongoin g basis during eDiary use (Day 1 to 
Day 7) or longer if events are not resolved.  
1. The Subject eDiary will be designed in such a way as to prevent  any blank, incomplete or 
biologically implausible entries during eDiary completion. Subj ects will be instructed to fully 
complete the Subject eDiary eac h day, as per the instructions p rovided. 
2. Before or just after vaccination , site staff must ensure that each subject’s eDiary is prepared  
for data capture in the ensuing post-vaccination period. 
3. Any new safety information reported during the site visit (incl uding a solicited reaction) 
cannot be entered into the Subject eDiary. Such information must be described in the source notes as a verbally-reported event. Any adverse reaction report ed in this fashion must be 
described as an unsolicited reaction and therefore entered on t he adverse event page of the 
eCRF. 
Electronic Case Report Forms  
This study utilizes electronic Case Report Forms (eCRFs) to col lect study-related data from each 
subject. A qualified site staff member(s) is required to enter subject data in the eCRFs in English 
based on the medical information a vailable in each subject’s so urce record.  
Data should be entered into the eCRF in a timely fashion follow ing each subject’s clinic visit, study 
procedure, or phone call. Each subject’s eCRF casebook will be compared with the subject’s source 
records by a Sponsor-approved study monitor (or designee) over the duration of the study in order to 
ensure data collection accuracy.  
3.7 Collection of Clinical Specimens  
The following clinical specimens are required to be collected f rom subjects in this study:  
x Blood at Days 1, 29, and 181. 
x Urine at Day 1 for females of childbearing potential in order to rule out any pregnancy.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 31 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   The processing of each specimen should be completed by a qualified site member and in accordance 
with the study-specific manual. See Clinical Specimen Laboratory Manual for additional details. The 
testing of clinical specimens (with the exception of the pregna ncy test) will be performed by [CONTACT_577276]. Refer to the study-specific Clinical Specimen Laboratory Manual for additional details.  
Blood Specimens  
Approximately [ADDRESS_757434] will be approximately 30 mL.  
In addition, subjects between 50-64 years of age (maximum of 50  subjects) may be asked to 
voluntarily provide an extra blood sample of [ADDRESS_757435] is 
eligible to provide this extra blood sample.  
Urine Specimens  
Urine will be collected for pregnancy testing in females of chi ldbearing potential. Urine will be 
collected on Day 1  before vaccination, results will be recorded in the source docu ment and eCRF. 
Testing will be done on the study site.  
3.8 Stoppi[INVESTIGATOR_007]/Pausing Guidelines  
aQIVc has never been administered to humans. Therefore, additio nal safety precautions have been 
included in this study. The IST, which is independent of the cl inical study team involved in the 
execution of the study, will review the safety information at t wo timepoints during the study conduct, 
using pause rules as provided in Table 3-1. Safety reviews by [CONTACT_577277] a 
7-day safety follow-up data are available for the first [ADDRESS_757436], the enrolment into the study and study vaccination will be paused pending the independent 
Data Monitoring Committee (DMC) review. It is the Sponsor’s res ponsibility to put the enrolment 
(or the study vaccination) on hold at all sites via the IRT. Th e DMC will review all available safety 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 32 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   data and make a recommendation to the Sponsor whether the study  should be permanently stopped, 
modified or continue unchanged. The final decision will be made  by [CONTACT_577278] (and, if needed, the Investigators). The decision will be documented and provided in writing 
to the investigators.  
Independent of the DMC, the Sponsor can halt the study at any t ime. If the study is halted, the Sponsor 
or delegate will promptly notify the health authorities and inv estigators, who will promptly inform 
the study subjects and local Ethics Committee/ Institutional Re view Board (EC/IRB) as per local 
regulations. Study vaccinations and further enrolment will only  occur after written authorization is 
provided by [CONTACT_577279] a recommendation to proceed by [CONTACT_577280]/IRB, as appropr iate. 
Table 3-1: Pause Rules for Planned IST Review  
No Pause Rule Criteria No. of subjects 
1 Any SAE that cannot be reasonably attributed to a cause other 
than vaccinationa, according to the Investigator’s assessment , 
within [ADDRESS_757437] -vaccination.  ≥[ADDRESS_757438]  
2 Severe systemic hypersensitivity such as anaphylaxis, within 
24 hours after study vaccination.  ≥[ADDRESS_757439]  
3 Any Grade 3  (severe) local solicited AE lasting ≥2 consecutive 
days, within 7 days postvaccination  ≥25% (and ≥2 subjects ) in aQIVc group 
4 Any Grade 3 (severe) systemic solicited AE lasting ≥2 
consecutive days, within 7 days postvaccination  ≥25% (and ≥2 subjects ) in aQIVc group 
5 Any severe unsolicited AE that cannot be reasonably 
attributed to a cause other than vaccinationa, withi n 7 days 
postvaccination  ≥10% (and ≥2 subjects ) in aQIVc group 
Notes: a at least probably related. Abbreviations: AE = adverse event; aQIVc = MF59-adjuvanted Quadrivalent Subunit Inactivated 
Cell-derived Influenza Vaccine  IST = internal safety team; No.  = number; SAE = serious advesre event.  
 
3.[ADDRESS_757440] level, as appropriate. The responsibilities, roles, and  procedures (including blinding) of the 
IST and DMC are described in the I ST Charter and DMC Charter.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 33 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757441] 
proceed to full completion of planned sample size accrual.  
Evaluation of the primary and/or secondary immunogenicity objectives requires the testing of biological samples from the study subjects, which can only be c ompleted after all samples are 
collected. The last samples for the analysis of the primary and /or secondary objectives will be taken 
on Day 181. For the purpose of this protocol, the end of study is defined as the completion of the 
testing of such biological samples, to be achieved no later than [ADDRESS_757442] eDiary, 
return for all the follow-up v isits and will be available for t he telephone calls as scheduled in the study. In some 
situations  support from a caregiver is allowed for the complet ion of the eDiary; this is up to the judgement of the 
Investigator.  
1 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 34 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757443] not me et ANY of the exclusion criteria described 
below:  
1. Females of childbearing potential who are pregnant, lactating, or who have not adhered to a 
specified set of contraceptive methods from at least [ADDRESS_757444].  
5. Known history of Guillain Barré syndrome or another demyelinati ng disease such as 
encephalomyelitis and transverse myelitis.  
6. Clinical conditions representing a contraindication to intramuscular administration of vaccines or 
blood draw. 
7. Abnormal function of the immune system resulting from:  
a) Clinical conditions  
                                                 
[ADDRESS_757445] occurred after 
hysterectomy, after bilateral ooph orectomy, or iatrogenic ablat ion of ovarian function. 
3 The following birth control methods are considered effective: abstinence, hormonal contraception (such as oral, 
injection, transdermal patch, implant) if used for at least [ADDRESS_757446] six months prior to informed consent. 
1 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 35 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   b) Systemic administration of corticosteroids (PO/IV/IM)4  at a dose of ≥ 20 mg/day of 
prednisone or equivalent for more than 14 consecutive days with in 90 days prior to informed 
consent5.  
c) Administration of antineoplastic and immunomodulating agents or radiotherapy within [ADDRESS_757447]  within 30 days prior to 
vaccination.  
10. Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days 
(for live vaccines) prior to enrolment in this study or who are  planning to receive any vaccine 
within 28 days from the study vaccines.  
11. Study personnel or immediate family or household member of stud y personnel.  
12. Receipt of any influenza vaccine within 6 months prior to vacci nation in this study, or plan to 
receive an influenza vaccine during the study period.  
13.  Acute (severe) febrile illness (see  Section 4.3, Criteria for Delay of Vaccination ). 
14. Any other clinical condition that, in the opi[INVESTIGATOR_871], might interfere with the results of the study or pose additional risk to the subject due  to participation in the study.  
4.[ADDRESS_757448] a 
transient clinical circumstance, such as an infection, which ma y warrant delay of vaccination: body 
temperature elevation [≥38.0° C (≥ 100.4° F)] within 3 days pri or to intended study vaccination, or 
acute use of any systemic antipyretics and/or analgesic medicat ions within [ADDRESS_757449] may be conside red eligible for study enrolment 
after the appropriate window for the delay has passed and inclu sion/exclusion criteria have been 
rechecked, and if the subject is confirmed to be eligible.  
                                                 
4 PO= by [CONTACT_1966]; IV=intravenous; IM= intramuscular 
5  Topi[INVESTIGATOR_2855], inhaled and intranasal co rticosteroids are permitted. Intermitted use (one dose in 30 days) of intra-articular 
corticosteroids are also permitted. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 36 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757450] effects occur and/or for safet y reasons. In addition, a subject may 
be withdrawn by [CONTACT_577281]/she viola tes the study plan or for administrative 
reasons. The investigator or study coordinator must notify the Sponsor immediately when a subject 
has been withdrawn due to an adverse event.  
The circumstances above are referred to as premature withdrawal  from the study, and the reason for 
premature withdrawal should be clearly documented and detailed in the source documentation and 
eCRF. The investigator should make every attempt to evaluate th e subject’s safety, including the 
resolution of ongoing AEs, at the time of premature withdrawal.  If a subject wants to withdraw from 
the study before the vaccine is administered or prior to the la st planned study visit, the subject will 
be asked to be followed for safety for the duration of the stud y. When a subject withdraws or is 
withdrawn, from the study, the procedures described in Section 5.6.1, Early Termination Visit  should 
be completed if possible. Subjects that have been prematurely w ithdrawn from the study will not be 
replaced.  
Any subject who becomes pregnant during the study, despi[INVESTIGATOR_577248], should be encourage d to continue participating i n the study for safety follow-up. The 
site must complete a Pregnancy Report eCRF (initial report) as soon as possible after learning of 
pregnancy occurrence (see Section 7.1.6, Pregnancies  for further details). If the pregnant subject 
withdraws from the study for any of the below categories except  death, the site will obtain permission 
from the subject to continue to remain in contact [CONTACT_577282] l the outcome of the pregnancy is 
known, even if the outcome is not known until after the subject reaches the end of the follow-up 
period.  
The reasons for premature withdrawal from the study include; Ad verse event, death, withdrawal of 
consent, lost to follow-up, and protocol deviation. These reaso ns are described in greater detail below. 
Adverse Event  
For any subject withdrawn from study participation prior to the  planned End of Study Visit, it is 
important to determine if an AE was associated with the reason for discontinuing the study. This AE 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 37 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757451] be identified on the AE eCRF page by [CONTACT_124439] “Withdrawn  from the study due to AE”. Any 
ongoing AEs at the time of study withdrawal must be followed un til resolution or stabilization.  
Death  
For any subject withdrawn from study participation due to death , this should be noted on the Study 
Completion eCRF page and the asso ciated SAE that led to the death must be reported.  
Withdrawal of consent  
The subject can withdraw consent for participation in the study  at any time without penalty or loss 
of benefit to which the subject i s otherwise entitled. The reas on for early termination should be 
deemed as “withdrawal of consent” if the subject withdraws from  participation due to a non-medical 
reason (i.e., a reason other than AE). If the subject intends t o withdraw consent from the study, the 
investigator should clarify and document if the subject will wi thdraw completely from the study or 
if the subject will continue study participation for safety, or  a subset of other study procedures. If the 
subject requests complete withdrawal from the study, no further  study interventions will be performed 
with the subject.  
If a subject withdraws consent but does not revoke the HIPAA au thorization (only applicable to US 
sites), the Sponsor will have full access to the subject’s medical records, including early termination 
visit information. If a subject revokes only the HIPAA authoriz ation, the Sponsor will have full access 
to all of the subject’s medical records prior to the date and time of written revocation.  
Lost to Follow-Up  
For subjects who fail to show up for the Study Completion visit , or for three consecutive visits (clinic 
or telephone contacts), study staff are encouraged to make at l east three documented attempts to 
contact [CONTACT_577283]. These efforts to contact [CONTACT_537354]. The terminat ion date for the subject to be captured 
on the End of Study eCRF page is the date of the last successfu l contact (clinic visit or telephone) 
with the subject.  
Other Reasons  
Examples for subjects withdrawn from the study due to an “other ” reason can include: the Sponsor’s 
decision to terminate the study, subject meeting a pre-specifie d withdrawal criterion, subject 
discontinuation for insurance issues, moving, no time, etc. This reason should be noted at the End of 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 38 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757452] be followed until 
resolution/stabilization. Note: If the clinical study is premat urely terminated by [CONTACT_1034], the 
investigator is to promptly inform the study subjects and local  EC/IRB and should assure appropriate 
therapy and follow up for the subjects. All procedures and requ irements pertaining to the archiving 
of study documents should be followed. All other study material s (study medication/vaccines, etc.) 
must be returned to the Sponsor.  
Protocol Deviation  
A protocol deviation is any change, divergence, or departure fr om the study design or procedures of 
a study protocol. In general, subjects associated with protocol  deviations may remain in the study 
unless continuation in the study jeopardizes the subject’s heal th, safety, or rights.  
Investigators will apply due diligence to avoid protocol deviat ions. Under no circumstances should 
the investigator contact [CONTACT_76630], if any, mon itoring the study to request approval of 
a protocol deviation, as no authorized deviations are permitted . If the investigator feels a change to 
the protocol would improve the conduct of the study this must b e considered a protocol amendment, 
and unless such an amendment is agreed upon by [CONTACT_95351]/EC and 
health authorities it cannot be implemented.  
5 STUDY PROCEDURES  
The sections that follow provide an overview of the procedures that are to be followed in enrolling, 
evaluating, and following subjects who participate in this clin ical study. Visits can be either clinic 
visits or safety follow-up telephone calls, as specified in both Table 0-1 and below in Table 5-1.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 39 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Table 5-1: Study Procedures  
Visit Category  Procedures  
Pre-vaccination Procedures and Vaccination 
Clinic Visit  Section 5.1  describes procedures to be followed 
prior to study vaccination: informed consent, 
screening, enrolment, and randomization, and 
blood draw. Section 5.2  and Section 5.3 describe 
procedures to be followed during the clinic visit 
for vaccination: vaccination and immediate 
post-vaccination procedures.  
Post-vaccination Visits  Section 5.[ADDRESS_757453] (may include early termination visit).  
 
5.1 Pre-vaccination Procedures: Screening/Randomization 
This section describes the procedures that must be performed fo r each potential subject prior to 
vaccination, including obtaining informed consent/assent, scree ning, enrolment, and randomization.  
5.1.[ADDRESS_757454] sufficient 
knowledge and understanding of the nature of the proposed research, the anticipated risks, and 
potential benefits, and the requirements of the research to be able to make an informed decision.  
Informed consent following local IRB/EC guidance must  be obtained before conducting any study-
specific procedure (i.e., all of the procedures described in th e protocol). The informed consent process 
may be conducted earlier, but within [ADDRESS_757455] source document in addition to maintaining a copy of the signed and dated informed consent. Additional specifics 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 40 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757456] cannot read, and who re ads the informed consent form (ICF) 
and any other written information supplied to the subject. Afte r the written ICF and any other written 
information to be provided to subjects, is read and explained t o the subject  and after the subject  has 
verbally consented to the subject’s participation in the study and, if capable of doing so, has signed 
and personally dated the informed consent form, the witness sho uld sign and personally date the 
consent form. By [CONTACT_17317], the witness attests that the information in the consent 
form and any other written information was accurately explained  to, and apparently understood by, 
the subject and that informed consent was freely given by [CONTACT_941] s ubject.  
5.1.[ADDRESS_757457] ’s unique Screening Number will 
be documented in the Screening and Enrolment log. The eligibili ty of the subject will be determined 
based on the inclusion and exclusion criteria listed in Section 4, Selection of Study Population  and 
evaluated during this screening procedure.  
The medical history will also be collected, including but not l imited to any medical history that may 
be relevant to subject eligibility for study participation such  as prior influenza vaccination in the [ADDRESS_757458] enrolment, concomitant medications, and previous and ongoing illnesses or 
injuries. Relevant medical history can also include any medical history that contributes to the understanding of an adverse event that occurs during study part icipation if it represents an 
exacerbation of an underlying disease/pre-existing problem. In case a subject is recruited from 
outside the clinic, verbal recall of medical history and associ ated concomitant medication is 
acceptable if medical records are not available.  
If applicable, prior and concomitant medications or vaccination s should be collected (refer to Section 
6.5, Prior and Concomitant Medications and Vaccines for further details). The use of any systemic 
analgesics and/or antipyretics within 24 hours prior to vaccina tion is a criterion for delay of 
vaccination (see Section 4.3, Criteria for Delay of Vaccination ).  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 41 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Also, on a separate eCRF, data to quantify the risk of complica tions from influenza will be collected. 
The ‘Prediction Rule for Estimating the Probability of Hospi[INVESTIGATOR_577249] ( Hak et al. 2004 ) found in Appendix 1 , will be used. The risk 
assessment, which incorporates comorbidity among other baseline  characteristics such as outpatient 
visits during the previous year and previous hospi[INVESTIGATOR_602] d ue to pneumonia or influenza, is a 
validated predictor of the risk of  complications from influenza  in elderly subjects. Using this model, 
a score of <50 is considered low risk and a score of ≥ 50 is co nsidered high risk. Determination of 
pre-existing medical conditions should be made by [CONTACT_577284]. The investigators will be given guidance for the completion of the eCRF.  
Pre-vaccination body temperature (preferably oral) will be collected. If body temperature is ≥38.0°C/ 
≥100.4°F at the time of screening, vaccination must be postponed until 3 days after the fever has 
resolved (see Section 4.3, Criteria for Delay of Vaccination ). Height and weight will also be 
measured. Measurements must be conducted by a trained health care professional. For women of childbearing potential, a pregnancy test should be performed (s ee Section 3.7, Collection of Clinical 
Specimens ).  
A general physical examination is to be performed by a qualifie d health care practitioner. These data 
will be written in the source document (see  Section 9.1, Source Documentation ). Should the physical 
assessment reveal any abnormal values or events, these must be documented in the eCRF.  
In the event that the individual is determined ineligible for s tudy participation, he/she is considered 
a screen failure. Re-screening with a new screening number, or further attempts to enroll or 
randomize the subject are not permitted. The reason for screen failure must be documented in the 
Screening and Enrolment log. If the individual is determined to  be eligible for the study, he/she will 
be enrolled in the study.  
5.1.[ADDRESS_757459] using the IRT system. Stra tification information should be 
provided before randomization.  
5.1.4 Randomization 
Enrolled subjects will be randomized to one of the four treatme nt groups in a 1:1:1:1 ratio with 
stratification factors for age (≥50 to 64 years and ≥65 years) and history of any influenza vaccination 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 42 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   within 3 previous influenza seasons (yes/no). Approximately 40%  of subjects in each age subgroup 
for each treatment group should not have been vaccinated within  the [ADDRESS_757460] will be randomized in the IRT/RTSM system. The subject will receive a unique Subject 
ID that will be used for all eCRFs and associated study documen tation for the duration of the study. 
After randomization, th e Screening Number ceases to be used and  remains in the Screening and 
Enrolment Log only. The list of randomization assignments is pr oduced by [CONTACT_577285] ’s Standard Operating Procedure 
(SOP). 
If for any reason, after signing the ICF, the subject who is el igible and enrolled fails to be randomized, 
this is called a randomization failure and the early termination study procedures must be applied. The 
reason for all randomization failures should be recorded in the  Screening and Enrolment Log and in 
the source document. The information on subjects who are randomization failures should be kept 
distinct from subjects who are screen failures, as described in  Section 5.1.2, Screening .  
If for any reason, after randomization the subject fails to und ergo treatment, the subject has to be 
discontinued, and the reason should be recorded at the End of Study CRF. The information on discontinued subjects should be kept distinct in the source doc umentation from randomization 
failures.  
5.1.5 Blood Draw  
Prior to vaccination, approximately 10 mL of blood will be draw n from subjects for the 
immunogenicity testing (see Section 3.7, Collection of Clinical Specimens ). 
5.[ADDRESS_757461] is eligible and does 
not meet any criteria for delaying study vaccination as describ ed in  Section 4.3 .  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 43 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757462]-vaccination AE’s (unsolicited adverse events). R ecord all safety data collected during 
this time in the subject’s source document.  
Subject eDiary Training  
A Subject eDiary will be dispensed (provisioned device or their  own device) in this study to document 
solicited adverse events. The Subject eDiary is the only source  for the collection of these data; 
therefore, it is critical that the subject completes the Subjec t eDiary correctly. The subject should be 
trained on how and when to complete each field of the Subject eDiary.  
The subject should be trained on how to self-measure local soli cited adverse events and body 
temperature. The measurement of solicited local adverse events is to be performed using the ruler 
provided by [CONTACT_779].  
The subject should be instructed on how to perform body tempera ture measurement using the 
thermometer provided by [CONTACT_779]. If the subject feels unusuall y hot or cold during the day, the subject 
should check body temperature. If the subject has a fever, the highest body temperature observed that 
day should be recorded in the Subject eDiary.  
Subject eDiary training should be directed at the individual(s)  who will perform the measurements 
of adverse events and who will enter the information into the Subject eDiary. In some situations, the Subject eDiary may be completed by [CONTACT_577286], e.g. caregiver, spouse, partner 
(except study site personnel). If a person other than the subje ct enters information into the Subject 
eDiary, the reason that the subject cannot complete their own eDiary and the person’s identity and relationship to the subject must be documented in the subject’s source. Any individual that makes entries into the eDiary must receive training on completion of the eDiary at the time of the visit. This 
training must be documented in the subject’s source. Ideally, t he same individual should complete 
the eDiary throughout the course of the study. Refer to the study-specific eDiary Manual for additional details on the assignment and use.  
Subject Compliance: Subjects should start to complete the eDiar y on the day of vaccination for 7 
consecutive days (or longer if the events are not resolved). Di ary data should be submitted every day. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 44 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Note: The subject must be contact[CONTACT_363974] [ADDRESS_757463] should be reminded of the next planned study activity; a safety phone call on Day 7. The subject will be reminded to complete the Subject eDiary and to contact [CONTACT_267693], and to contact [CONTACT_29261] (or as soon as t he subject is medically stable) if the 
subject has a medical condition that leads to a hospi[INVESTIGATOR_577250] a visit 
to/by a doctor or is otherwise of concern.  
5.3.[ADDRESS_757464] eDiary  device’s in-built audio-visual alarms 
to alert the user to complete the diary during the post-vaccina tion period. From Day [ADDRESS_757465] the presence (yes/no) of any 
medically attended (defined as symptoms or illnesses requiring hospi[INVESTIGATOR_059], or emergency room 
visit, or visit to/by a health care provider) unsolicited AE, o r any unsolicited AE of concern. In case 
of such events, the subject will be instructed to contact [CONTACT_941] s ite as soon as possible to report the 
event(s).  
The Subject eDiary system will also allow for regular alerts to  be issued via email to site staff 
indicating when subjects may need to be contact[CONTACT_577287]:  
x Non-compliance (i.e. failing to enter or transmit diary data),  
x Reporting of any severe solicited reactions.  
Sites must assess these alerts when received and contact [CONTACT_363977]. Contact [CONTACT_363978]. Please ref er to Section 4.5, Premature 
Withdrawal from Study  and 7.1.3, Evaluation of Adverse Events  for guidance on necessary action in 
the event of one of these alerts.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 45 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757466]-vaccination clinic visits or safety calls will be performe d on: Day 7 (Safety Phone Call), Day 
29 (Clinic Visit), Day 91 (Safety Phone Call) and Day 181 (Clin ic Visit).  
5.4.[ADDRESS_757467]-vaccination clinic visits will be performed on Day 29 (visit 3), and at Day 181 (visit 5) (see 
Section 5.6 for assessments to be performed at Study Completion Visit). In the event that a clinic 
visit is not possible, a home visit may be considered.  
During the follow-up clinic visit on Day 29, the subject will b e interviewed to determine if any 
unsolicited AEs occurred including SAEs, AESIs, MAAEs, and if a ny concomitant medications or 
vaccines were taken/received in the time since the last clinic visit. The qualified healthcare 
professional reviewing these data will discuss the symptoms (if  any) reported by [CONTACT_438835]/or adverse events are  present. Adverse events reported by 
[CONTACT_363979]-up clinic visit must be recorded in the subject's source document and on an 
AE eCRF, as specified in Section 7.1, Safety Assessments . 
If applicable, a qualified heal thcare professional will perform  a targeted  physical examination if 
necessary based on specific complaints indicated by [CONTACT_423]. 
The subject will be asked to return any electronic device that was provisioned for the collection of 
the solicited AEs, if applicable.During the visit, approximatel y 10 mL of blood will be drawn from 
all subjects (see  Section 3.7, Collection of Clinical Specimens ). Additionally, an extra blood sample 
of 50 mL will be drawn from subjects (maximum of 50 subjects) w ho agreed to provide a blood 
sample, for future research not related to this study.  
In addition, the site should schedule the next study activity, a safety phone call on Day 91, with the 
subject. The subject will be reminded to contact [CONTACT_577288] (or as soon as the subject is medically stable ) if the subject has a medical condition 
that leads to hospi[INVESTIGATOR_577251].  
5.4.2 Safety Follow-up Calls 
Safety follow-up calls will  be performed on Days 7 and 91.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 46 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757468] by a qualified healthcare professional designated 
on the site’s roles and responsibilities log. These calls will follow a script as guidance, which will 
facilitate the collection of relevant safety information. The s ubject will be interviewed, and 
information relating to unsolicited adverse events. The followi ng unsolicited adverse events will be 
collected:  
Day [ADDRESS_757469] the site immediately (or as soon 
as the subject is medically stable) if the subject has a medica l condition that leads to hospi[INVESTIGATOR_577252].  
5.[ADDRESS_757470] (clinic visit or tel ephone call) in which the subject’s health 
status was assessed or, in cases where the subject does not agree to any further safety follow-up, it is the date consent is withdrawn. This date should be recorded at the end of the Study eCRF page. For 
visit procedures to be performed for a subject whose planned st udy participation ends prematurely, 
please see Section 5.6.1, Early Termination Visit .  
During the study completion clinic visit, the subject will be i nterviewed to determine if any SAEs, 
AESIs or medically attended adverse events occurred and if any associated concomitant medications 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 47 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   or vaccines were taken/received in the time since the last safe ty assessment. The qualified healthcare 
professional reviewing these data will discuss the symptoms (if  any) reported by [CONTACT_438835]/or adverse events are  present. Adverse events reported by 
[CONTACT_363979]-up clinic visit must be recorded in the subject's source document and on an 
Adverse Events eCRF, as specified in Section 7.1, Safety Assessments .  
If applicable, a qualified healthcare professional will perform  a targeted  physical examination based 
on specific complaints indicated by [CONTACT_423]. This is a phys ical examination that will include an 
examination of organ systems that are relevant to the investiga tor based on a review of the subject’s 
reported influenza complications and the use of medication to treat these complications.  
During the visit, approximately 10 mL of blood will be drawn fr om all subjects (see  Section 3.7, 
Collection of Clinical Specimens ). 
The site will review with the subject the plan of when informat ion relating to the subject’s 
participation in the study may be available (e.g., study result s, treatment assignments). It will also be 
discussed how information relating to the subject’s participati on in the study will be shared with the 
subject’s healthcare provider if the subject chooses to share t his information.  
The site will complete the end of the Study eCRF page and this will mark the completion of the 
subject’s participation in the study.  
5.6.[ADDRESS_757471] discontinues the study, the investigator will pe rform the safety assessment procedures 
during study completion (see Section 5.6, Study Completion Visit ). The reason(s) for the early 
termination will be included in the subject’s source documentat ion. If the Early Termination Visit is 
a telephone call, collect as much information as possible. Earl y Termination Visits include subjects 
who were randomized but not treated and subjects who were eligi ble and enrolled but failed to be 
randomized.  
The site will review with the subject the plan of when informat ion relating to the subject’s 
participation in the study may be available (e.g., study result s, treatment assignments). It will also be 
discussed how information relating to the subject’s participation in the study will be shared with the 
subject’s healthcare provider if the subject chooses to share t his information.  
The site will complete the end of the Study eCRF page and this will mark the completion of the subject’s participation in the study.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 48 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757472] n ot be administered to subjects,  as specified in Section 6.6, Vaccine 
Supply, Labeling, Storage and Tracking and in the Investigators Manual .  
6.1 Study Vaccine(s)  
The term ‘study vaccine’ refers to those vaccines provided by [CONTACT_1034], which will be evaluated 
as part of the study objectives. The study vaccines specific to  this study are described below.  
Investigational Vaccine: aQIVc  
Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine , which includes MF59 adjuvant. 
HA antigens are derived from the four influenza virus strains ( A/H1N1, A/H3N2, B/Yamagata and 
Victoria lineage) recommended by [CONTACT_14300] (World Health Organiza tion) for quadrivalent vaccines 
for the respective season.  of each HA antigen i s present in 0.5 mL of the vaccine, 
which is formulated in a pre-filled syringe (PFS). The full com position of the vaccine is reported in 
Table 6-1.  

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 49 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Table 6-1: aQIVc Vaccine Composition  
Name [CONTACT_577341] 
0.5mL dose Function 
Active Ingredients 
HA and NA antigens from the influenza virus strains 
recommended by [CONTACT_577289] 
x Strain A1 (H1N1 subtype) 
x Strain A2 (H3N2 subtype) 
x Strain B1 (B/Victoria lineage) 
x Strain B2 (B/Yamagata lineage)  
 HA 
(per strain)  
 
  
HA Antigen  
(active ingredient)  
 
Adjuvant   
Squalene  Oil phase 
Polysorbate 80  Surfactant 
Sorbitan trioleate  Surfactant 
Sodium citrate  Buffer 
Citric acid  Buffer 
Other Ingredients   
Phosphate-buffered saline   
Sodium chloride  Isotonic acid 
Potassium chloride  Isotonic acid 
Magnesium chloride hexahydrate  Stabilizer 
Disodium phosphate dihydrate  Buffer 
Potassium dihydrogen phosphate  Buffer 
Water for injection Up to 0.50 mL Diluent 
*   
Notes:*  residues of special relevance are MDCK cell protein ( ), protein other than HA ( ), MDCK cell 
deoxyribonuclei c acid (DNA) ( ), cetyltrimethlyammonium bromide (CTAB) ( ), beta -propi[INVESTIGATOR_188811] ( ), 
polysorbate 80 ( ), and sorbitan trioleate ( ).  Abbreviations: aQIVc = MF59- adjuvanted Quadrivalent Subunit 
inactivated cell-derived Influenza Vaccine; CTAB = cetyltrimeth lyammonium bromide; DNA = deoxyribonucleic acid; HA = 
hemagglutinin; MDCK = Madin-Darby [CONTACT_155664]; NA = neuramini dase; WHO = World Health Organization.  
 
Comparator vaccine: aQIV  
Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine,  which includes MF59 adjuvant. 
HA antigens are derived from the four influenza virus strains ( A/H1N1, A/H3N2, B/Yamagata and 
Victoria lineage) recommended by [CONTACT_577290]. 
Fifteen (15) μg of each HA antigen is present in 0.5 mL of the vaccine, which is formulated in a PFS. 
The full composition of the vaccine is reported in  Table 6-2.  

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 50 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                    
Table 6-2: aQIV Vaccine Composition  
Names of Ingredients  Quantity per 0.5 mL dose Function 
Active Ingredients 
HA and NA  antigens from the influenza virus strains 
recommended by [CONTACT_577291]  
A/ (H1N1)  
A/ (H3N2)  
B/ (Yamagata lineage)  
B/ (Victoria lineage) 15 μg HA 
(per strain) 
 Active ingredient 
Adjuvant   
Squalene 9.75 mg oil phase 
Polysorbate 80 1.175 mg Surfactant 
Sorbitan trioleate  1.175 mg Surfactant 
Sodium citrate 0.66 mg Buffer 
Citric acid 0.04 mg Buffer 
Other Ingredients 
Buffer    
 Sodium chloride  Isotonic aid 
 Potassium chloride  Buffer 
 Potassium dihydrogen phosphate  Buffer 
 Disodium phosphate dihydrate  Buffer 
 Magnesium chloride hexahydrate  Stabiliser 
 Calcium chloride dihydrate  Stabiliser 
 Water for injection up to 0.50 mL Diluent 
*   
Notes: *residues of special relev ance are cetyltrimethlyammoniu m bromide (CTAB), chicken proteins such as ovalbumin, 
formaldehyde, kanamycin and neomycin sulphate. Abbreviations: a QIV = MF59-adjuvanted Quadrivalent Subunit Inactivated egg-
derived Influenza Vaccine; CTAB = cetyltrimethlyammonium bromid e; HA = hemagglutinin; NA = neuraminidase; WHO = World 
Health Organization 
  

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 51 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Comparator vaccine: QIVc  
Non-adjuvanted Quadrivalent Subunit Inactivated Cell-derived In fluenza Vaccine. HA antigens are 
derived from the four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) 
recommended by [CONTACT_577292]. Fifteen (15) μg of 
each HA antigen is present in 0.5 mL of the vaccine, which is formulated in a PFS. The full 
composition of the vaccine is reported in Table 6-3 . 
 
Table 6-3: QIVc Vaccine Composition  
Names of Ingredients  Quantity per 0.5 mL dose Function 
Active Ingredients 
HA a nd  NA antigens from the influenza virus strains 
recommended by [CONTACT_577293] e of 
influenza vaccine for the season  
A/ (H1N1)  
A/ (H3N2)  
B/ (Yamagata lineage)  
B/ (Victoria lineage) 15 μg HA 
(per strain) 
 Active ingredient 
Other Ingredients   
Buffer M (PBS) pH 7.2    
 Sodium chloride  Isotonic aid 
 Potassium chloride  Buffer 
 Magnesium chloride hexahydrate  Stabilizer 
 Disodium hydrogen phosphate dihydrate  Buffer 
 Potassium dihydrogen phosphate  Buffer 
 Water for injection Up to 0.5 mL Diluent 
*   
Notes: * residues of special relev ance are cetyltrimethlyammoni um bromide (CTAB), polysorbate 80, and β-propi[INVESTIGATOR_188811]. 
Abbreviations: CTAB = cetyltrimethlyammonium bromide; HA = hema gglutinin; NA = neuraminida se; QIVc = Quadrivalent 
Subunit Inactivated Cell-derived Influenza Vaccine; WHO = World  Health Organization.  
 
Comparator vaccine: QIVr  
Recombinant Quadrivalent Influenza Vaccine HA antigens are deri ved from the four influenza virus 
strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recom mended by [CONTACT_577294]. Forty-five (45 ) μg of each HA antigen is present in 

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 52 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   0.5 mL of the vaccine, which is formulated in a PFS. The full composition of the vaccine is reported 
in Table 6-4.  
Table 6-4: QIVr Vaccine Composition  
Names of Ingredients Quantity per 0.5 mL dose Function 
Active Ingredients 
HA antigens from the influenza virus strains 
recommended by [CONTACT_577291]  
A/ (H1N1)  
A/ (H3N2)  
B/ (Yamagata lineage)  
B/ (Victoria lineage) 45 μg HA 
(per strain) 
 Active ingredient 
Other Ingredients   
Sodium Chloride  4.4 mg Isotonic Acid 
Monobasic sodium phosphate 0.195 mg Inorganic salt 
Dibasic sodium phosphate 1.3 mg Buffer 
Polysorbate 20 27.5 μg Solubilizing agent 
Triton X-100 ≤ 100 μg Detergent 
*   
Notes:* residues of special relev ance are baculovirus and Spodo ptera frugiperda cell proteins (≤ 19 μg), baculovirus and cell ular 
DNA (≤ 10 ng), and Triton X -100 (≤ 100 μg).  Abbreviations: DNA = deoxyribonucleic acid; HA = hemagglutinin ; QIVr = 
Recombinant Quadrivalent Influenza Vaccine; WHO = World Health Organization. 
 
6.2 Non-Study Vaccines  
Non-study vaccines will not be provided by [CONTACT_577295].  
6.3 Vaccine Preparation and Administration  
The investigator or designee will be responsible for oversight of the administration of the vaccine to 
subjects enrolled in the study according to the procedures stip ulated in this study protocol. Refer to 
the Investigator’s Manual for additional details. All vaccines will be administered only by [CONTACT_577296].  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 53 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   All vaccines are to be provided in PFS, each with an injectable  volume of approximately 0.5 mL. 
The full volume contained in the PFS is to be administered.  
Vaccination will be performed intramuscularly, preferably in th e deltoid muscle of the non-dominant 
arm. Detailed administration instructions will be provided to i nvestigators prior to the study start.  
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY V ACCINE:  
Prior to vaccination, subjects mu st be determined to be eligibl e for study vaccination and it must be 
clinically appropriate in the judgment of the investigator to v accinate. Eligibility for vaccination prior 
to first study vaccine administration is determined by [CONTACT_577297] 4.1, Inclusion Criteria and 4.2, Exclusion Criteria . 
Delay of study vaccination is determined by [CONTACT_577298] 4.3, Criteria 
for Delay of Vaccination . 
Study vaccines should not be administered to individuals with known hypersensitivity to any 
component of the vaccines.  
Standard immunization practices a re to be observed and care sho uld be taken to administer the 
injection intramuscularly. Before administering the vaccine, th e vaccination site is to be disinfected 
with a skin disinfectant (e.g., 70% alcohol). Allow the skin to  dry. DO NOT inject intravascularly.  
As with all injectable vaccines, trained medical personnel and appropriate medical treatment should 
be readily available in case of anaphylactic reactions following vaccine administration. For example, 
epi[INVESTIGATOR_238] 1:1000, diphenhydramine, and/or other medications for treating anaphylaxis should be 
available.  
6.4 Vaccine Administration Error or Overdose of Vaccine  
Vaccine administration error is defined as receiving a dose of study vaccine that was administered by 
a different route from the intended route of administration. An  overdose of study vaccine (whether 
accidental or intentional) is defined when a dosage higher than the recommended dosage is 
administered in one dose of study vaccine as per the dosing reg imen described in Section 6.1, Study 
Vaccines.  
Any vaccine administration error or overdose of study vaccine d etailed in this protocol must be 
reported as an adverse event and as a Protocol Deviation. If th e vaccine administration error or 
overdose is associated with a serious adverse event (SAE), it must be reported as such within 24 
hours to the Sponsor.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 54 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757473]’s source records. For each season 
it will be recorded in the eCRF whether the subject was vaccina ted (yes/no), including the type of 
vaccination (if available). In addition, the date of the last i nfluenza vaccination and the source of the 
influenza history (recall or medical source) will be captured i n the eCRF. All subjects who received 
at least one influenza vaccination within [ADDRESS_757474]’s medical history are to be re corded on the Concomitant Medications 
and Non-Study Vaccinations eCRF.  
In addition, all medications and vaccines described in the inclusion and exclusion criteria are 
considered prior medications for this protocol, including:  
x Immunoglobulins or any blood products within [ADDRESS_757475] within 3 0 days prior to informed 
consent. 
x Systemic administration of corticosteroids (PO/IV/IM) at a dose of ≥20 mg /day of prednisone 
or equivalent for more than [ADDRESS_757476] should 
not be enrolled in the study.  
The use of antipyretics and/or analgesic medications within [ADDRESS_757477] be 
identified and the reason for their use (prophylaxis versus tre atment) must be described in the source 
document and Concomitant Medications eCRF. The use of antipyret ics/analgesics within 24 hours 
prior to vaccine administration is a reason to delay study vaccination (see  Section 4.3, Criteria for 
Delay of Vaccination ).  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 55 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Medications taken for prophylaxis are those intended to prevent  the onset of symptoms. Medications 
taken for treatment are intende d to reduce or eliminate the pre sence of symptoms that are present.  
Concomitant medications and vaccines  
Concomitant medications include  all medications (including vacc ines) taken by/administered to the 
subject at and after enrolment and must be documented on the Co ncomitant Medications eCRF.  
The following concomitant med ications will be recorded in the Concomitant Medications CRF: 
x All concomitant medications from Day [ADDRESS_757478] (other  than the study vaccines) 
during the entire study period (from Visit 1 to study completio n). 
In addition, the use of the following concomitant medications after enrolment until end Day [ADDRESS_757479] on the 
interpretation of the study objectives and therefore if used, m ay be determined to be a reason for 
exclusion from one of the analysis sets.  
x Blood, blood products or a parenteral  immunoglobulin preparatio n.  
x Oral or systemic corticosteroids. 
x Other immunomodulating agents. 
6.6 Vaccine Supply, Labeling, Storage and Tracking  
The Sponsor will ensure the following:  
x Supply the study of vaccines.  
x Appropriate labeling of all study  vaccines  provided, that complies with the legal requirements of 
each country where the study is to be performed.  
x Appropriate storage and distribution of study vaccines. 
The investigator must ensure the following:  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 56 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   x Acknowledge receipt of the study vaccines by a designated staff  member at the site, including:  
– Confirmation that the vaccines were received in good condition and in the right amount  
– Confirmation to the Sponsor of the temperature range during shi pment from the Sponsor to 
the investigator’s designated storage location in the correct r ange (2°C to 8°C/ 36°F to 46°F)  
– Report any temperature deviation and do not use vaccines until further confirmation by [CONTACT_577299].  
x Proper storage of the study vaccines, including:  
– Storage in a secure, locked, temperature-controlled location.  
– Proper storage according to the instructions specified on the l abels and in the Investigators 
Manual.  
– Appropriate record-keepi[INVESTIGATOR_299878],  including regular 
documentation of adequa te storage temperature.  
x Appropriate use of the study vaccines, including:  
– Not use of vaccines prior to receipt of authorization for use from the Sponsor.  
– Use only in accordance with the approved protocol.  
– Proper handling, including confirmation that the vaccine has no t expi[INVESTIGATOR_299879].  
– Appropriate documentation of the a dministration of vaccines to study subjects including:  
o Date, dosage, batch/lot numbers, expi[INVESTIGATOR_1659], unique ident ifying numbers 
assigned to subjects and study vaccines, and time of vaccine ad ministration. This 
information will be maintained in an accountability log that wi ll be reviewed by [CONTACT_363991].  
o Reconciliation of all vaccines received from the Sponsor. Recon ciliation is defined as 
maintaining records of which and how many vaccines were receive d, which vaccines 
were administered to subjects, which vaccines were destroyed at the site, and which 
vaccines were returned to the Sponsor, as applicable.  
x Proper adherence to the local institutional policy with respect  to the destruction of study vaccines.  
x Complete record keepi[INVESTIGATOR_29216], wastage, return or dest ruction, including documentation 
of: 
– Copy of the site’s proced ure
 for the destruction of hazardous m aterial.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 57 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   – The number of doses destroyed, date of destruction, destruction  code (if available), method 
of destruction, and name [CONTACT_577342] l performing destruction.  
Vaccines that have been stored differently from the manufacture r’s indications must not  be used 
unless the Sponsor provides written authorization for use. In t he event that their use cannot be 
authorized, the Sponsor will make every effort to replace the v accine supply. All vaccines used in 
conjunction with this protocol must be stored separately from n ormal hospi[INVESTIGATOR_307]/practice stocks to 
prevent unintentional use of study vaccines outside of the clinical study setting.  
Monitoring of vaccine accountability will be performed by [CONTACT_363992].  
At the conclusion of the study, and as appropriate during the c ourse of the study, the investigator 
must ensure that all unused study vaccines, packaging, and supp lementary labels are destroyed 
locally (upon approval from the  Sponsor) or returned to the Spo nsor.  
[ADDRESS_757480] a causal 
relationship with this treatment. Therefore, an AE can be any u nfavorable and unintended sign 
(including an abnormal laboratory finding, for example), sympto m, or disease temporally associated 
with the use of an investigational product, whether or not considered related to the investigational product. This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing conditions.  
The period of observation for AEs extends from the time the subject signs informed consent until he or she completes the specified safety follow-up period of 180 d ays or terminates early (whichever 
comes first). AEs occurring after the informed consent form is signed but prior to receiving the study 
vaccine will be documented as an adverse event and recorded wit hin the source document. However, 
any AEs occurring prior to receipt of any study vaccine will be  analyzed separately from “treatment-
emergent” AEs (AEs occurring after administration of the study vaccine). Adverse events are 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 58 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757481] Diaries or interviews.  
7.1.1 Solicited Adverse Events 
The term “reactogenicity” refers to solicited signs and symptom s (“solicited adverse events”) 
occurring in the hours and days following vaccination, to be co llected by [CONTACT_256856] 7 consecutive 
days (Day 1 to Day 7), using a pre-defined Subject eDiary. If a  solicited local or systemic adverse 
event continues beyond day [ADDRESS_757482] eDiary.  
Each solicited AE is to be assessed according to a defined seve rity grading scale;  see specifics of the 
solicited event and grading system below in Table 7-1.  
Table 7-1: Severity Grading for Solicited Local and Systemic Adverse Events  
Solicited Event Grade 1/Mild Grade 2/Moderate Grade 3/Severe 
Injection site pain No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Erythema 25-50 mm 51-100 mm > 100 mm 
Induration 25-50 mm 51-100 mm > [ADDRESS_757483] on normal 
activity Eating less than usual 
/interfered with normal 
activity Not eating at all 
Nausea No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Fatigue No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Myalgia No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Arthralgia No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Headache No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Chills No interference with daily 
activity Interferes with daily 
activity Prevents daily activity 
Fever 38.0 - 38.4 °C 
100.4 – 101.1 °F 38.5 – 38.9 °C 
101.2 – 102.0 °F ≥39.0 °C  
≥102.1 °F 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 59 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Other Indicators of Reactogenicity  
The use of analgesics/antipyretics will be captured as “absent”  or “present” separately by [CONTACT_48933] “for 
treatment” or “for prevention”. 
The study staff must review the data entered into the Subject e Diary as described in Section 3.6.2, 
Tools Used for Data Collection  and Section 5.4, Post-vaccination Visits.  
Note: Any solicited AE that meets any of the following criteria  must be entered into subjects’ source 
document (see Section 9.1, Source Documentation ) and also as an AE on the AE eCRF:  
x Solicited local or systemic AE that leads to an unscheduled visit to a healthcare provider (MAAE, 
see Section 7.1.3, Evaluation of Adverse Events ).  
x Solicited local or systemic AE leading to the subject withdrawi ng from the study or the subject 
being withdrawn from the study by [CONTACT_093] (AE leading to withdrawal, see Section 7.1.3, 
Evaluation of Adverse Events ). 
x Solicited local or systemic AE that otherwise meets the definit ion of a serious AE (see Section 
7.1.4, Serious Adverse Events ). 
7.1.[ADDRESS_757484] who has signed the informed consent.  
Potential unsolicited AEs may be medically attended (defined as  symptoms or illnesses requiring 
hospi[INVESTIGATOR_059], or emergency room visit, or visit to/by a health care provider), or were of concern to 
the subject. In case of such events, subjects will be instructe d to contact [CONTACT_577300](s). The detailed information about the repo rted unsolicited AEs will be collected 
by [CONTACT_577301] b e documented in the subject’s records . 
The period of observation for AEs extends from the time of info rmed consent until the subject either 
completes the specified safety follow-up period (Day 181) or at early study termination.  
All unsolicited AEs that start during the treatment period (Day  1 to Day 29) will be recorded in the 
eCRF. During the follow-up (Day 30 to Day 181), unsolicited AEs  that meet any reporting criterion 
(an SAE, AESI, AE leading to withdrawal or a MAAE) are to be re corded in the eCRF.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 60 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757485] 
for an underlying diagnosis and to capture this diagnosis as th e event on the AE page. In other words, 
the practice of reporting only symptoms (e.g., “cough” or “ear pain”) are better reported according 
to the underlying cause (e.g., “as thma exacerbation” or “otitis  media”).  
The severity of events reporte d on the AE eCRF will be determined by [CONTACT_1694]:  
Mild:  transient with no limitation in normal daily activity.  
Moderate:  some limitations in normal daily activity.  
Severe:  unable to perform normal daily activity.  
The relationship of the study treatment to an unsolicited AE wi ll be determined by [CONTACT_98286]:  
1. Not Related 
The AE is not related to an investigational vaccine if there is evidence that clearly indicates an 
alternative explanation. If the subject has not received the va ccine, the timing of the exposure to the 
vaccine and the onset of the AE is not reasonably related in time, or other facts, evidence or arguments 
exist that reasonably suggest an alternative explanation, then the AE is not related.  
2. Possibly Related  
The administration of the invest igational vaccine and AE are co nsidered reasonably related in time 
and the AE could be explained by [CONTACT_577302] l vaccine or by [CONTACT_22714].  
3. Probably Related  
Exposure to the investigational vaccine and AE are reasonably r elated in time and no alternative 
explanation has been identified.  
The relationship of the study treatment to an unsolicited AE wi ll be determined by [CONTACT_093].  
Adverse events will also be evaluated by [CONTACT_1732] t he co-existence of any of the other 
following conditions:  
x Medically attended adverse even t: An AE that leads to a visit to a healthcare provider. 
x AESI see Section [IP_ADDRESS], Adverse Events of Special Interest . 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 61 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   x AEs leading to withdrawal: adverse events leading to study with drawal.  
If solicited or unsolicited AEs have been reported and the subject indicated that the symptoms 
required medical attendance or were of concern, the subject mus t be contact[CONTACT_141917].  
When the subject is contact[CONTACT_363996], the con tact must be documented in the 
subject’s source documentation.  
All AEs, regardless of severity, will be monitored until resolution or until the investigator assesses them as chronic or stable. All subjects experiencing AEs - whether considered associated with the 
use of the study vaccine or not - must be monitored until sympt oms subside and any abnormal 
laboratory values have returned to baseline, or until there is a satisfactory explanation for the changes 
observed, or until death, in which case a full pathologist’s re port should be supplied, if possible. The 
investigator’s assessment of ongoing AEs at the time of each su bject’s last visit should be 
documented in the subject’s medical chart. 
7.1.[ADDRESS_757486] medical occurrence that at an y dose results in one or more of the 
following:  
x Death. 
x Is life-threatening (i.e., the subject was, in the opi[INVESTIGATOR_1101] t he investigator, at immediate risk of 
death from the event as it occurred); it does not refer to an e vent which hypothetically might have 
caused death if it were more severe. 
x Required or prolonged hospi[INVESTIGATOR_059]. 
x Persistent or significant disability/incapacity (i.e., the even t causes a substantial disruption of a 
person’s ability to conduct normal life functions).  
x Congenital anomaly/or birth defect. 
x An important and significant medical event that may not be imme diately life-threatening or 
resulting in death or hospi[INVESTIGATOR_313], based upon appropria te medical judgment, may 
jeopardize the subject or may require intervention to prevent o ne of the other outcomes listed 
above. 
Adverse events that do not fall into these categories are defin ed as non-serious. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 62 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   It should be noted that a severe AEs need not be serious in nature and that an SAE need not, by 
[CONTACT_108], be severe.  
All SAEs will be evaluated by [CONTACT_577303]. 
SAEs that are judged to be possibly or probably related to the study vaccine should be reported to 
the Sponsor as related/suspected events.  
The relationship of the study treatment to an SAE will be deter mined by [CONTACT_363998]:  
1. Related/suspected  
The SAE is judged by [CONTACT_577304] y related to the study vaccine on the 
AE eCRF page (see Section 7.1.3, Evaluation of Adverse Events ). 
2. Not Related 
The SAE is not related if exposure to the study vaccine has not  occurred, or the occurrence of the 
SAE is not reasonably related in time, or the SAE is considered unlikely to be related to using of the 
study vaccine, i.e., there are no facts (evidence) or arguments  to suggest a causal relationship.  
The relationship of the study vaccine to an SAE will be determined by [CONTACT_093].  
In addition, SAEs will be evaluated by [CONTACT_299936] “expectedness.” An unexpected 
AE is one that is not listed in the current Product Information or the Investigator’s Brochure or an event that is by [CONTACT_29288] a lis ted event.  
Pre-existing event or condition that results in hospi[INVESTIGATOR_577253]. In addition, the worsening of a pre-existing even t should be reported as an AE as 
described in Sections 5.1.2, Screening and 7.1.2, Unsolicited Adverse Events. If the onset of an event 
occurred before the subject entered the study (e.g., any pre-pl anned hospi[INVESTIGATOR_577254]-emergency routine visits fo r a pre-existing condition), the 
hospi[INVESTIGATOR_577255], in the view of the 
investigator, hospi[INVESTIGATOR_120513] a result of participation in the clinical study or was necessary due to a worsening of the pre-existing condition.  
[IP_ADDRESS] Adverse Events of Special Interest 
Adverse events of Special Interest (AESI)s are a pre-defined list of adverse events that are of potential immune-mediated medical conditions; the list can be found in Appendix 2.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 63 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757487] a potential AESI, she/he should promptly 
inform the investigator.  
A diagnosis of an AESI is to be reported in the same manner and  time frame as an SAE and will be 
captured on the AE eCRF. If the eCRF is not available, then the  study site must complete the paper 
SAE Report Form send to the Sponsor’s Pharmacovigilance and Risk Management (PVRM) (or 
delegate) at [EMAIL_10986] . The investigator must notify the Sponsor within [ADDRESS_757488]’s source documents and on the AE eCRF.  
7.1.[ADDRESS_757489]'s 
source document. 
All SAEs which occur during the course of the study, whether co nsidered to be associated with the 
study vaccination or not, must be documented on the AE eCRF within [ADDRESS_757490] complete  the paper SAE Report Form and 
send it to the Sponsor's PVRM (or delegate) at [EMAIL_10986]  within 24 hours of 
becoming aware. Once the eCRF is available , the SAE should be documented on the  AE eCRF as 
soon as possible.  
Any medication or other therapeutic measures used to treat the AE will be recorded on the appropriate 
eCRF(s) in addition to the outcome of the AE.  
After receipt of the initial report, representatives of the Sponsor or its designee will contact [CONTACT_577305] f or an assessment of the event.  
All SAEs must be reported by [CONTACT_299940]/her corres ponding EC/IRB or applicable 
regulatory authorities in accordance with institutional policy/regulatory requirements  and adequate 
documentation of this notification must be provided to the Spon sor. 
Sponsor or its designee must also comply with the applicable regulatory requirement(s) related to the 
reporting of suspected unexpected serious adverse vaccine reactions (S[LOCATION_003]Rs) to the regulatory 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 64 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   authority(ies) and the IRB/EC. If a S[LOCATION_003]R or other safety signal relating to the use of one of the 
study vaccines is reported to the Sponsor or its designee, the Sponsor will communicate the 
information to the investigator and the investigator will be re sponsible for submitting this information 
to the EC/IRB  and other relevant authorities.  
[IP_ADDRESS] Post-Study Events 
Any SAE that occurs outside of the protocol-specified observati on period or after the end of the study 
but is considered to be caused by [CONTACT_577306] (or 
delegate) and must be reported using the email address: [EMAIL_10986] . 
These SAEs will be considered as part of the spontaneous report ing towards the investigational study 
vaccine in order to ensure the safety of all subjects.  
7.1.[ADDRESS_757491] becomes pregnant after vaccination, confirmation o f pregnancy should be recorded in the 
eCRF. To ensure subjects’ safety, each pregnancy in a subject a fter study vaccination must be reported 
to the Sponsor’s PVRM (or delegate) within [ADDRESS_757492] complete the paper Pregnancy Reporting/Outcome Form a nd send it to 
[EMAIL_10986] . If the subject agrees to submit this information, the pregnancy  must be 
followed to determine the outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. This follow-up should occur even if the intended duration of safety follow-
up for the study has ended.  
Any pregnancy outcome meeting the definition of a SAE (see  Section 7.1.4, Serious Adverse Events ) 
must also be reporte d on the AE eCRF.  
7.1.7 Safety Laboratory Measurements 
No scheduled safety laboratory measurements are planned for thi s study.  
7.2 Efficacy Assessment  
There is no assessment of efficacy in this study.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 65 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757493],  i.e., widely used and generally 
recognized as reliable, accurate, and relevant (able to describ e the quality and extent of the immune 
response).  
The immunogenicity analysis will evaluate the immunogenicity of the study vaccine, which will be 
measured by [CONTACT_577307].  
For the primary immunogenicity objectives, HI antibody response s using a cell-derived target virus 
will be evaluated for all strai ns. In case of a lack of aggluti nation for a specific strain using HI assay, 
immunogenicity for that strain will be assessed as measured by [CONTACT_364005].  
For the secondary immunogenicity objectives, HI and MN antibody  responses using cell-derived 
target virus will be evaluated for all strains. In case of a la ck of agglutination for a specific strain 
using HI assay, immunogenicity for that strain will be assessed  as measured by [CONTACT_364005].  
For the exploratory immunogenicity evaluation, HI antibody resp onses may be evaluated for all strain 
using egg-derived target viruses.  
Testing will be conducted by [CONTACT_577308] a blinded manner towards the 
treatment arm.  
8 STATISTICAL CONSIDERATIONS  
A complete description of the statistical analyses and methods will be available in the Statistical 
Analysis Plan, which will be finalized before the database is l ocked for the primary analysis. The 
primary analysis will be conducted on the immunogenicity and safety data collected up to Day 29.  
8.1 Endpoints  
8.1.1 Primary Endpoint(s) 
The primary objective of the study is to assess the immunogenicity of aQIVc compared to QIVc, aQIV , and QIVr as measured by [CONTACT_577309]-derived  target viruses. The primary endpoints 
are therefore the set of immunogenicity endpoints routinely applied for studies with such objectives.    
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
Document #: FORM1-000107830, Ed: 1.0 
Source Doc umen
t #: SOP-000056619  Page 66 of 91 
Effective Date: See System Metadata  Confidential Print Date (Local): 30-mrt-2020 10:41:00 [IP_ADDRESS] Primary Immunogenicity Endpoints 
Humoral immune response in terms of HI antibody response agains t homologous cell-derived 
vaccine strains (A/H1N1, A/H3N2, B/Yamagata and B/Victoria):  
x Geometric Mean Titer (GMT): Geometric mean of HI antibodies at Day 29;  
x Geometric Mean Fold Increase (GMFI): The Geometric mean of the fold increase in serum 
HI GMTs post-vaccination (Day 29) compared to pre-vaccination ( Day 1);  
x Percentages of subjects with HI titers ≥ 1:40 at Day 29;  
x Percentage of subjects with seroconversion (defined as a ≥ 4-fold increase in titer post-
vaccination in those with pre-vaccination titer above the LLOQ (1:10), or a post-vaccination titer 
≥ 1:40 for subjects with baseline titer below the LLOQ (1:10) for HI antibodies at Day 29).  
Note that the HI assay could be replaced by [CONTACT_577310] a lack of agglutination. 
[IP_ADDRESS] Primary Safety Endpoints 
No primary  saf
ety endpo ints have been defined.  
8.1.2 Secondary Endpoints 
Secondar
y e
ndpoints assessed in the study include the safety en dpoints of solicited and unsolicited 
adverse events, the immunogenicity endpoints measured by [CONTACT_577311] 181 and in 
addition the immunogenicity endpoints measu
red by [CONTACT_577312] 29 and day 181.   
[IP_ADDRESS] Secondary Safety Endp
oints 
The secondary safety endpoints include the propor tion of subjec ts reporting solicited and unsolicited 
adverse
 events: 
-Percentage of subjects reporting a local and/or systemic adverse event for the 7 days following
the vaccination (Day 1 to Day 7)
-Percentage of subjects reporting unsolicited adverse events for 28 days following vaccination(Day 1 to Day 29).
-Percentage of subjects reporting serious AEs, MA AEs, AEs leadi ng to withdrawal or AESIs
as collected during the study (Day 1 to End of Study).
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 67 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   [IP_ADDRESS] Secondary Immunogenicity Endpoints 
Humoral immune response in terms of HI antibody response agains t homologous cell-derived 
vaccine strains (A/H1N1, A/H3N2, B/Yamagata and B/Victoria) at Day 181:  
x GMT: Geometric mean of HI antibodies at Day 181;  
x GMFI: The Geometric mean of the fold increase in serum HI GMTs post-vaccination (Day 
181) compared to pre-vaccination (Day 1);  
x Percentages of subjects with HI titers ≥ 1:[ADDRESS_757494] homologous 
cell-derived  vaccine strains (A/H1N1, A/H3N 2, B/Yamagata and B/Victoria) at Days 29 and 181:  
x GMT: Geometric mean of MN antibodies at Days 29 and 181;  
x GMFI: The Geometric mean of the fold increase in serum MN GMTs post-vaccination (Day 
29 and Day 181) compared to pre-vaccination (Day 1);  
x Percentages of subjects with seroconversion (defined as ≥ 4-fol d increase for subjects with 
pre-vaccination MN titers ≥ Lower Limit of Quantitation (LLOQ) or as ≥ 4LLOQ for subjects 
with pre-vaccination MN titer <LLOQ) at Day 29.  
8.1.3 Exploratory Endpoints 
Exploratory endpoints that may be assessed in the study include  the immunogenicity endpoints as 
measured by [CONTACT_577313]-derived  target viruses on Day 29, 28 days after vaccination. Refer 
to the SAP for more details.  
[IP_ADDRESS] Exploratory Safety Endpoints 
No exploratory safety endpoints were defined.  
[IP_ADDRESS] Exploratory Immunogenicity Endpoints 
Humoral immune response in terms of HI antibody response agains t homologous egg-derived  
vaccine strains (A/H1N1, A/H3N2, B/Yamagata and B/Victoria):  
x GMT: Geometric mean of HI antibodies at Day 29;  
x GMFI: The Geometric mean of the fold increase in serum HI GMTs post-vaccination (Day 
29) compared to pre-vaccination (Day 1);  
x Percentages of subjects with HI titers ≥ 1:40 at Day 29;  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 68 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   x Percentage of subjects with seroconversion for HI antibodies on Day 29. 
 
The results of these exploratory analyses may be presented in a n addendum to the Clinical Study 
Report (CSR)  
8.2 Success Criteria  
This study is a Phase 2 study to explore the immunogenicity of aQIVc versus comparator vaccines 
(QIVc, aQIV, and QIVr). No success criteria are pre-specified.  
8.[ADDRESS_757495] ID and provide demographic 
and/or baseline screening assessments, regardless of the subjec t’s randomization and treatment status 
in the study  
8.3.2 All Exposed Set 
All subjects in the All Enrolled Set who are randomized and rec eived  study vaccination.  
8.3.3 Safety Set 
Solicited Safety Set  
All subjects in the Exposed Set with any solicited adverse even t data including temperature 
measurements or use of analgesics/antipyretics.   
Unsolicited Safety Set (unsolicited adverse events)  
All subjects in the Exposed Set with unsolicited adverse event data.  
Overall Safety Set  
All subjects who are in the Solic ited Safety Set or in the Unso licited Safety Set.  
Subjects will be analyzed as “tre ated” (i.e., according to the vaccine a subject received, rather than 
the vaccine to which the subject may have been randomized).  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 69 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   8.3.4 Full Analysis Set (FAS) Immunogenicity  
Full Analysis Set Immunogenicity  
All subjects in the All Enrolled Set who are randomized, receiv ed study vaccination and provided 
immunogenicity data on Day 1 and Day 29 assessment.  
In case of vaccination error, subjects in the FAS sets will be analyzed “as-treated” (i.e., according to 
the vaccine the subject actually received).  
8.3.5 Per Protocol Set (PPS) Immunogenicity 
All subjects in the FAS Immunogenicity who: 
x Correctly receive the vaccine (i.e., receive the vaccine to whi ch the subject is randomized and at 
the scheduled time point). 
x Have no protocol deviations leading to exclusion (see Section 8.3.8, Protocol Deviations ) as 
defined prior to unblinding / analysis. 
x Are not excluded due to other reasons defined prior to unblindi ng or analysis, including subjects 
who withdrew informed consent prior to Day 28.   
8.3.6 Other Analysis Sets 
Not applicable  
8.3.7 Subgroups 
Primary and secondary analyses of immunogenicity and safety end points will be done for the total 
population and by [CONTACT_56328] (50 – 64 years and ≥ 65 years).  
Additional subgroup analysis will be conducted for previous vaccination history. Refer to the SAP 
for further details.  
8.3.8 Protocol Deviations 
A protocol deviation is any change, divergence, or departure fr om the study design or procedures of 
a study protocol. A protocol deviation may be a reason to remov e data from an analysis set at the 
time of analysis. CSR-reportable protocol deviations will be defined as exclusionary from the 
analysis according to protocol objectives and endpoints, which will be specified in the statistical 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 70 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   analysis plan. In some cases, exclusion of data may be due to a  reason other than a protocol deviation, 
e.g. early termination.  
8.4 Statistical Analysis Plan  
8.4.1 Analysis of Demographic and Baseline Characteristics  
Descriptive statistics (mean, standard deviation, median, minimum and maximum) for age, height, 
weight, BMI and comorbidity score at enrolment will be calculated overall and by [CONTACT_29299].  
Distributions of subjects by [CONTACT_4321], race and ethnic origin, prior vaccination status and site will be 
summarized overall and by [CONTACT_29299].  
Demographic and baseline characteristics will also be presented  by [CONTACT_577314].  
8.4.2 Analysis of Primary Objectives 
[IP_ADDRESS] Analysis of Primary Safety Objectives 
Not applicable.  
[IP_ADDRESS] Analysis of Primary Immunogenicity Objectives 
The primary objective is to assess the immunogenicity assessed using the HI assay at Day 29.  
[IP_ADDRESS].1 Statistical Hypothesis 
No statistical testing will be performed for the immunogenicity objectives.  
[IP_ADDRESS].2 Analysis Sets 
All immunogenicity objectives will be evaluated based on the PP S Immunogenicity. Only in case, 
more than 5% of subjects are excluded, additional analysis base d on the FAS Immunogenicity will 
be conducted.  
[IP_ADDRESS].3 Statistical Methods 
All statistical analyses for HI (and MN) titers will be perform ed on the logarithmically (base 10) 
transformed values. Individual HI titers below the detection li mit (<10) will be set to half of that limit 
(5); values above the upper limit of quantification will be set  to the upper limit.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 71 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Reverse cumulative distributi on curves will be derived by [CONTACT_5586]- point and strain.  
Crude estimates for GMTs, GMFIs and pertaining 2-sided 95% CIs will be calculated assuming a 
log-normal distribution of the titers and will be completed by [CONTACT_364010], maximum and 
median titers for each vaccine group. Binary data (i.e., percen tages of subjects with seroconversion 
and with titer ≥ 1:40) will be summarized for each group using crude estimates and will be reported 
together with 2-sided 95% CIs calculated according to Clopper P earson’s method. No multiplicity 
adjustment to the CI levels will be implemented.  
For immunogenicity data, it may be reasonable to consider missi ng immunogenicity values as 
missing completely at random (MCAR), i.e., not informative. The refore, the immunogenicity 
analysis will comprise a complete case analysis only, without i ntroducing any bias.  
The analysis model for the HI GMT will be done using a general linear model on log-transformed 
(base 10) Day 29 titers as the outcome variable and as covariat es: treatment groups (aQIVc, QIVc,  
aQIV , and QIVr), pre-vaccination titer, age stratum. From this model, adjusted differences in the least 
square means (on the log scale) will be produced with 95% confi dence limits for aQIVc versus QIVc, 
for aQIVc versus aQIV and for aQIVc versus QIVr. The estimated difference and the confidence 
limits will be back-transformed to obtain an adjusted GMT ratio with 95% confidence limits. Each 
of the four strains will be analyzed separately.  
Potential interaction between age stratum and treatment effect will be examined, as well as the other 
co-variates such as previous vaccination history and age were t aken as a continuous factor.  
A similar model will be used for the GMFI on Day 29.  
The binary endpoints (i.e. seroconversion or titer ≥1:40) will be compared using the Miettinen and 
Nurminen method without  adjustment for the age stratum. The results will be presented as the 
difference in the percentage of subjects with 95% confidence in tervals. Additional supportive 
analyses will be done using generalized  linear models with factors for vaccine group, age 
subgroup, pre-vaccination titer a s well as history of vaccination. Adjusted differences between 
vaccine groups with 2-sided 95% CI will be calculated based on the model and potential interaction 
effects will be examined.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 72 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   8.4.3 Analysis of Secondary Objectives 
[IP_ADDRESS] Analysis of Secondary Safety Objectives 
[IP_ADDRESS].1 Analysis of Extent of Exposure 
The number of subjects vaccinate d will be presented by [CONTACT_577315].  
[IP_ADDRESS].[ADDRESS_757496]-vaccination. 
A solicited adverse event will be  defined as “present” or at le ast mild on any of the recorded days to 
be counted. This will be summarized as total and for local, sys temic and the other category separately. 
The same tables will be created at each timepoint.   
Frequencies and percentages of subjects experiencing each adver se event will be presented overall 
and for each maximum symptom severity and by [CONTACT_29299]. Pos t-vaccination solicited adverse 
events reported from Day 1 to Day 7 will also be summarized for  the interval’s Day 1-3 and Day 4-
7 overall and for each maximal severity and by [CONTACT_29299].  
The severity of solicited local adverse events will be summariz ed according to the grading. For the 
categories based on linear measurement for local AEs erythema a nd induration: 25-50 mm is mild, 
51-100 mm is moderate and >100 mm is severe. Solicited local ad verse events measuring less than 
25 mm will  not be considered as an adverse event. For temperat ure: any fever is ≥ 38 °C and severe 
is ≥ 39 °C.  
The use of antipyretics and analgesics will be summarized by [CONTACT_577316] (prophylactic versus 
treatment) as the number and percentage of subjects reporting u se.  
Body temperature will be summarized by 0.5 °C increments from 3 6.0 °C up to ≥40 °C.  
[IP_ADDRESS].3 Analysis of Unsolicited Adverse Events 
This analysis applies to all AE’s occurring during the study, j udged either as probably related, 
possibly related, or not related to vaccination by [CONTACT_31691], recorded in the AE eCRF, with a 
start date on or after the date of vaccination. AE starting pri or to study vaccination will only be listed. 
The original verbatim terms used by [CONTACT_577317] a dverse events in the eCRFs will be 
mapped to preferred terms using the MedDRA dictionary.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 73 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757497] possibly 
related to study vaccine, will be summarized according to syste m organ class and the preferred term 
within system organ class. These summaries will be presented by  [CONTACT_577318] (Day 1 to Day 29, Day 30 to end o f study). When an AE occurs more 
than once for a subject, the maximal severity and strongest rel ationship to the vaccine group will be 
counted.  
Separate summaries will be produced for the following categorie s 
x AEs 
x SAEs 
x AEs that are possibly or probably related to the vaccine 
x SAEs that are possibly or probably related to the vaccine 
x AESIs 
x MAAEs 
x AEs leading to withdrawal 
Data listings of all adverse events will be provided by [CONTACT_74058]. In addition, adverse events in the 
categories above will be provided as listed data. 
[IP_ADDRESS].4 Statistical Hypotheses 
No statistical hypotheses will be tested  
[IP_ADDRESS].5 Analysis Sets 
Where applicable, the safety set will be used for the safety an alysis. The solicited safety set for the 
solicited adverse events and the  unsolicited safety set for all unsolicited adverse events.  
[IP_ADDRESS].6 Statistical Methods 
Only descriptive statistics will be calculated and presented.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 74 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   [IP_ADDRESS] Analysis of Secondary Immunogenicity Objective(s) 
The analysis of the secondary immunogenicity endpoints will be conducted in the same way as 
described for the primary immunogenicity endpoints.  
[IP_ADDRESS].1 Statistical Hypotheses 
No statistical hypotheses will be tested.  
[IP_ADDRESS].2 Analysis Sets 
All secondary immunogenicity objec tives will be evaluated based on the PPS Immunogenicity. Note 
that the PPS for the Day 181 analysis may exclude additional su bjects in case of major protocol 
deviations related to the use of concomitant medication interfe ring with the immunogenicity 
assessment. Only in case, more than 10% of subjects are exclude d, additional analysis based on the 
FAS Immunogenicity will be conducted.  
[IP_ADDRESS].3 Statistical Methods 
The statistical methods will follow the same methods as described for the primary endpoints in 
Section [IP_ADDRESS].3.  
8.4.4 Analysis of Other Objectives 
The exploratory analysis may be done based on the immunogenicit y endpoints by [CONTACT_577319]-derived target viruses. Results from these analyses will be reported separately.  
[IP_ADDRESS] Analysis of Other Safety Objectives 
No exploratory safety analysis was defined.  
[IP_ADDRESS] Analysis of Other Immun ogenicity Objectives 
The exploratory endpoints will be evaluated using the same meth ods as described above in  Section 
[IP_ADDRESS].3. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 75 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   8.5 Sample Size and Power Considerations of Primary Objectives  
This study is an exploratory P hase 2 study  without any formal i nferential analysis. The total sample 
size of 480 subjects has been determined by [CONTACT_577320].  
This sample size – including around 10% of exclusions – is enou gh to obtain preliminary 
immunogenicity data. Table 8-1 illustrates the effects which can be detected depending (80% p ower 
and the two-sided significance level of 0.05) on different valu es for the inter-subject variation, as 
well as the size of the 95% two-sided confidence interval indic ating the accuracy of the estimates.  
Table 8-1: Detectable GMT ratios  
SD # Log10 GMT Differences 
that can be detected  GMT ratios can be detected 95% confidence interval 
(times the GMT ratio) 
0.45 0.172 1.49 0.76 to 1.32 
0.50 0.191 1.55 0.73 to 1.36 
0.55 0.211 1.62 0.71 to 1.40 
0.60 0.230 1.70 0.69 to 1.45 
0.65 0.250 1.77 0.67 to 1.49 
0.7 0.268 1.85 0.65 to 1.54 
0.75 0.287 1.94 0.63 to 1.59 
0.80 0.306 2.02 0.61 to 1.64 
Notes: # range of values based on studies V7P38 and V70P3. Abbr eviations: GMT= geometric mean titer. SD = Standard deviation.  
 
8.6 Interim Analysis  
No interim analysis of data from this study is planned.  
Two final analyses will be performed stepwise as follows:  
1. A final analysis including all immunogenicity and safety dat a collected from Visit 1 to Visit 3 (Day 
29) and associated primary and secondary objectives will be conducted on cleaned and locked data. 
No individual listings and unblinding data will be generated at  this stage. Access to information about 
study groups will be limited by a biostatistic ian in charge of statistical analysis.  
2. The analysis of immunogenicity and safety data collected bet ween Visit 3 and Visit 5 will be 
performed after all data is available. The results of this anal ysis will cover the entire study duration. 
All results will be presented in the clinical study report and will include individual data listings and 
unblinded information.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 76 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   9 SOURCE DOCUMENTATION, STUDY MONITORING, AND AUDITING  
In order to ensure consistency across sites, monitoring and aud iting will be standardized and 
performed in accordance with the Sponsor’s or delegated contrac t research organization’s (CRO) 
standard operating procedures and applicable regulatory require ments (e.g., FDA, EMA, and ICH 
guidelines).  
Prior to the enrolment of the first study subject, the Sponsor or delegate will train investigators and/or 
their study staff on the study protocol, all applicable study procedures, documentation practices, and 
all electronic systems. eCRFs supplied by [CONTACT_299959] c ompleted for each enrolled subject 
(see Section 8.3.1, All Enrolled Set for the definition of the enrolled subject). Documentation of 
screened but not enrolled subjects must be maintained at the si te and made available for review by 
[CONTACT_25007]. Data and documents will be checked by [CONTACT_577321]/or monitor.  
9.[ADDRESS_757498]  include all of the following: subject identification (on each 
page), eligibility and participation, proper informed consent p rocedures, dates of visits, adherence to 
protocol procedures, adequate repo rting and follow-up of advers e events, documentation of 
prior/concomitant medication/vaccines, study vaccine receipt/di spensing/return records, study 
vaccine administration information, any data collected by a telephone conversation with the subject and date of completion and reason.  
The subject must also allow access to the subject’s medical records. Each subject must be informed of this prior to the start of the study and consent for access to medical records may be required in 
accordance with local regulations.  
All safety data reported by [CONTACT_577322]. If there are multiple sources of information ( e.g., Subject eDiary, verbal report of 
the subject, telephone contact [CONTACT_8972], medical chart) supporti ng the diagnosis of an adverse event, 
these sources must be identified in the source documents, discr epancies between sources clarified, 
the ultimate diagnosis must be justified and written in the source documents, and this diagnosis must be captured in the Adverse Event eCRF (AE eCRF).  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 77 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757499], the Sponsor or its designee (e.g., a CRO) will develop 
a Clinical Monitoring Plan to specify how centralized and/or on -site monitoring, including clinical 
specimens reconciliation, will be performed for the study. Study progress will be monitored by [CONTACT_577323]:  
x that the rights and well-being of human subjects are protected,  
x the reported study data are accura te, complete, and verifiable from the source documents and 
x the conduct of the study is in compliance with the current appr oved protocol/amendment(s), GCP 
and applicable regulatory requirements. 
Contact [CONTACT_577324]’s team or its designee involved  in study monitoring will be provided 
to the investigator. Study data recorded on eCRFs will be verif ied by [CONTACT_577325] a nd accuracy as required by [CONTACT_577326] 7, Assessments  being 
entered directly into the EDC system.  
Data verification may also be performed through a centralized r eview of data (e.g., checking for 
outliers or other anomalies). Additional documents such as the investigator site file, pharmacy 
records, and informed consent doc umentation must also be availa ble for review if requested. 
Arrangements for monitoring visits will be made in advance in a ccordance with the monitoring plan, 
except in case of an emergency.  
The investigator and/or site staff must make source documents of subjects enrolled in this study 
available for inspection by [CONTACT_13668] a t the time of each monitoring visit and 
Sponsor’s audits, when applicable. These documents must also be available for inspection, 
verification, and copying, as re quired by [CONTACT_19124], by [CONTACT_577327] 
(e.g., FDA, EMA, and others) and/or ECs/IRBs. The investigator and study site staff must comply 
with applicable privacy, data protection and medical confidenti ality laws for use and disclosure of 
information related to the study and enrolled subjects.
 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 78 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   10 DATA MANAGEMENT  
10.1 Data Entry and Management 
In this study, all clinical data (including, but not limited to , AE/SAEs, concomitant medications, 
medical history, and physical assessments) and blood sampling w ill be entered onto eCRFs in a timely 
fashion by [CONTACT_1755]/or the investigator’s dedicated site staff. Data entered onto eCRFs are 
stored on a secure website. The data collected on this secure w ebsite are assimilated into an electronic 
data capture (EDC) system, which is compliant with Title 21 Part 11 policies of the Code of Federal 
Regulations (FDA 1997 ). The data system includes pa ssword protection and internal qu ality checks. 
The EDC system will be designed and validated by [CONTACT_577328]. The investigator or designated delegate must review data  entered and electronically sign the 
eCRFs to verify their accuracy.  
Access to the EDC system for data entry or review will require training and distinct individual access 
code assignments to those site staff members who will be entering study data and those involved in 
study oversight who may review study data. Data are collected w ithin the EDC system, to which the 
Sponsor and site monitors have exclusively “read-only” access.  
10.[ADDRESS_757500] confirm and endorse the changes.  
10.3 Data Protection 
The sponsor respects the subjects’ rights to privacy and will e nsure the confidentiality of their medical 
information in accordance with all applicable laws and regulati ons. 
The Sponsor as Data Controller according to the General Data Pr otection Regulation (“GDPR”) on 
the protection of individuals with regard to the processing of personal data and on the free movement 
of such data confirms herewith compliance to GDPR in all stages of Data Management.
 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 79 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757501] consult th e Sponsor’s representative before 
disposal of any study records and must notify the Sponsor of any change in the location, disposition, 
or custody of the study files.  
The sponsor-specific essential documents should be retained unt il at least 2-years after the last 
approval of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2-years hav e elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents should be 
retained for a longer period however if required by [CONTACT_577329](s) or if 
needed by [CONTACT_456] ( ICH E6 (R2)).  
“Essential documents” are defined as documents that individuall y and collectively permit evaluation 
of the conduct of a study and the quality of the data produced. These documents should be retained for a longer period, however, if required by [CONTACT_577330] ( ICH E6 (R2) ). 
The sponsor should inform the investigator(s)/institution(s) in  writing of the need for record retention 
and should notify the investigator(s)/institution(s) in writing  when the trial-related records are no 
longer needed ( ICH E6 (R2) ). 
The principles of record retention will also be applied to the storage of laboratory samples, provided 
that the integrity of the stored sample permits testing. These laboratory samples will be securely 
stored for future testing at a global Sponsor’s or Sponsor’s- c ontrolled/contracted facility for up to 
[ADDRESS_757502]’s samples stored for future testing 
(not related to this study) afte r the study is completed, this can be indicated on the ICF.
 
12 USE OF INFORMATION AND PUBLICATION  
The Sponsor assures that the key design elements of this protoc ol will be posted in a publicly 
accessible database such as clinicaltrials.gov, and in complian ce with current regulations.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 80 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757503] editorial, ethical practices and cu rrent guidelines of Good Publication 
Practice ( Graf 2009 ), the Sponsor will generally support publication of multicente r studies only in 
their entirety and not as individual center data. In this case,  a coordinating investigator [INVESTIGATOR_363941].  The coordinating investigator [INVESTIGATOR_577256] ( CPMP/EWP/2747/00 ). 
Authorship will be determined by [CONTACT_577331]' authorship requirements. Any formal pu blication of the study in which the 
contribution of the Sponsor’s  personnel exceeded that of conventional monitoring will be cons idered 
as a joint publication by [CONTACT_577332]’s  personnel.  
The Sponsor must be notified of any intent to publish data coll ected from the study and prior approval 
from the Sponsor must be obtained prior to submission for publi cation. 
 
13 ETHICAL CONSIDERATIONS  
13.1 Regulatory and Ethical Compliance 
The study will be conducted in compliance with the protocol, GC P and applicable regulatory 
requirement(s).  
This clinical study was designed and shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice (ICH E6(R2 ), with applicable local 
regulations including  European Directive 2001/20/EC  and US Code of Federal Regulation s Title 21 , 
Sponsor’s codes on protection of human rights, and with the eth ical principles laid down in the 
Declaration of Helsinki ( European Council 2001, US Code of Federal Regulations, ICH 1997 ). 
13.[ADDRESS_757504] 
informed consent and any other materials that will be provided to the subjects reviewed and approved by [CONTACT_1201]/EC. This review and approval will be documented and stored with other study documents. The investigator or designee must fully inform the subject of a ll pertinent aspects of the study. A copy 
of the written informed consent will be given to the subject. The subject must be allowed ample time 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 81 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757505] be agreed to by [CONTACT_577333]/E C and a copy of the approved 
version must be provided to the Sponsor monitor after IRB/EC approval.  
Women of childbearing potential should be informed that taking the study medication may involve 
unknown risks to the fetus if the pregnancy were to occur durin g the study and agree that in order to 
participate in the study they must adhere to the contraception requirements indicated in the protocol 
for the duration of the study. If the case of doubts on the abi lity of a subject to adhering to these 
requirements, that subject should not be allowed in the study  
13.3 Responsibilities of the Investigator and IRB/IEC 
The protocol and the proposed informed consent form must be rev iewed and approved by a properly 
constituted IRB/EC before the study start. Properly constituted IRB/EC is defined in the integrated 
addendum to ICH E6: ICH Guideline for Good Clinical Practice E6 (R2) . A signed and dated 
statement that the protocol and informed consent have been approved by [CONTACT_1201]/EC must be given 
to the Sponsor before study initiation. Prior to study start and at any time the protocol is amended during study conduct, the investigator is required to sign a pr otocol signature [CONTACT_5389]/her 
agreement to conduct the study in accordance with these documen ts and all of the instructions and 
procedures found in this protocol and to give access to all rel evant data and records to the Sponsor’s 
monitors, auditors, Sponsor’s Clinical Quality Assurance repres entatives, designated agents of the 
Sponsor, IRBs/ECs, and regulatory authorities as required. If a n inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform the Sponsor immediately that this request has been made.  
The investigator also responsible for the following:  
x Maintaining a list of appropriately qualified persons to whom t he investigator has delegated 
significant study-related duties. 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 82 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757506](s), and their study-related duties and functions 
x Ensuring that appropriately trained health care professionals a re responsible for all study-related 
medical decisions and for ensuring appropriate medical care of subjects experiencing any adverse 
event related to the study. 
x If permission to do so is given by [CONTACT_423], ensuring that t he subject’s primary healthcare 
provider is informed of the subject’s parti cipation in the study. 
The investigator should not implement any deviation from, or changes of the protocol without 
agreement by [CONTACT_577334]/favorable opi[INVESTIGATOR_120973]/IEC of an amendment, except where necessary to eliminate an  immediate hazard(s) to study 
subjects, or when the change(s) involves only logistical or adm inistrative aspects of the study (e.g., 
change in monitor(s), change of telephone number(s). In additio n, the investigator, or person 
designated by [CONTACT_093], should document and explain any deviation from the approved protocol.  
The investigator may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to study subjects without prior IRB/IEC app roval/favorable opi[INVESTIGATOR_1649]. As soon as 
possible, the implemented deviation or change, the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be submitted:  
(a) to the IRB/IEC for review  and approval/favorable opi[INVESTIGATOR_1649],  
(b) to the Sponsor for agreement and, if required,  
(c) to the regulatory authority(ies).  
13.4 Protocol Amendments 
An amendment is a written description of change(s) to or formal  clarification of a study protocol 
which may impact on the conduct of the clinical study, potential benefit of the clinical study, or may 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 83 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757507] safety (e.g., change of telephone number(s), 
logistical changes). Protocol amendments must be approved by [CONTACT_3433] e Sponsor, health authorities where 
required, and the IRB/EC. In cases when the amendment is requir ed in order to protect the subject's 
safety urgently, the amendment can be implemented prior to IRB/ EC approval. Notwithstanding, the 
need for formal approval of a protocol amendment, the investiga tor is expected to take any immediate 
action required for the safety of any subject included in this study, even if this action represents a 
deviation from the protocol. In such cases, the Sponsor should be notified of this action, the IRB/EC 
at the study site, and, if required by [CONTACT_427], the r elevant health authority) should be 
informed within [ADDRESS_757508]  
Calabro S, Totroli M, Baudner BC, Paccito A et al. Vaccine adju vants alum and MF59 induce rapid 
recruitment of neutrophils and monocytes that participate in an tigen transport to draining lymph 
nodes. Vaccine. 2011;29(9):1812-23.  
Centers for Disease Control and Prevention, 2019a. Seasonal Inf luenza (Flu), Types of Influenza 
Vaccines. November 18, 2019 [Accessed December 23, 2019] Availa ble from 
https://www.cdc.gov/flu/about/viruses/types.htm . 
Centers for Disease Control and Prevention, 2019b. Past seasons estimated influenza disease burden. 
November 22, 2019 [Assessed December 23, 2019]. Available from:  
https://www.cdc.gov/flu/about/burden/2017-2018.htm.   
Code of Federal Regulations, 1997: Food and Drug Administration , U.S. Department of Health and 
Human Services: Title 21, Part 1 1: Electronic Records Electroni c Signatures. Federal Register 
62:[ZIP_CODE]. 
Committee for Medicinal Products for Human Use. Note for guidan ce on coordinating investigator 
[INVESTIGATOR_363943] ( CPMP/EWP/2747/00 ). 
European Parliament, 2001. Directive 2001/20/EC of the European Parliament and of the Council of 
4 April 2001. Official Journal of the European Communities. L 1 21/34-44.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 84 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   Frey SE, Reyes MR, Reynales H, Bermal NN, et al. Comparison of the safety and immunogenicity 
of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza  vaccine in elderly subjects. 
Vaccine. 2014;32(39):5027-5034.  
Graf C, Battisti WP, Bridges D. Good publication practice for c ommunicating company Sponsored 
medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. 
Hak E, Wei F, Nordin J, Mullooly J et al. Development and validation of a clinical prediction rule for 
hospi[INVESTIGATOR_577257]-dwelling elderly persons. J Infectious Diseases. 2004;189:450-8. 
Hedge N. Cell culture-based influenza vaccines: A necessary and  indispensable investment for the 
future. Human vaccines and Immunotherapeutics. 2015;11(5):1223- 1234  
ICH E6 (R2), 2016. ICH Harmonized Tripartite ICH Guideline for Good Clinical Practices E6 (R2), 
EMA/CHMP/ICH/135/1995.  
Iuliano A, Roguski K, Chang HH, Muscatello D et al. Estimates o f global seasonal influenza-
associated respi[INVESTIGATOR_211254]: A modeling study. Lancet. 2018;391([ZIP_CODE]):1285-1300.  
Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl  J Med. 2010;363:2036-44. 
McNeil, M. Vaccine-associated anaphylaxis. Curr Treat Options A llergy. 2019;6:297–308 
O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately 
attractive adjuvant formulation. Vaccine. 2012;30(29):4341-8. R eview Erratum in Vaccine. 
2013;31(14):1877.  
Reber AJ, Chirkova T, Kim JH, Cao W et al. Immunosenescence and  challenges of vaccination 
against influenza in the aging population. Aging and Disease. 2012;3:68-90.  
Roshini S and Miller J. Is the influenza vaccine effective in d ecreasing infection, hospi[INVESTIGATOR_059], 
pneumonia, and mortality in healthy adults? OSMAJ. 2019;112(3): 86–87. 
Sasaki S and Sullivan M. Limited efficacy of inactivated influe nza vaccine in elderly individual is 
associated with decreased production of vaccine-specific antibo dies. J Clin Invest. 
2011;121(8):3109-3119.  
Temte J and Prunuske J. Seasonal influenza in primary care settings: Review for primary care physicians. WMJ. 2010;109(4):193-200.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 85 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   World Health Organization, 2018. Influenza (seasonal) Factsheet, November 2018 [accessed 6 
December 2018]; Available from: http://www.who.int/mediacentre/ factsheets/fs211/en/  
Wong SS and Webby [CONTACT_265957]. Traditional and new influenza vaccines. C linical Microbiology Reviews. 
2013;26:476-92.  
Zhou H, Thompson WW, Viboud CG, Ringholz CM, et al. Hospi[INVESTIGATOR_577258], 1993-[ADDRESS_757509] Dis. 2012;54(10):1427-
1436.  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 86 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   APPENDIX 1 – HAK SCORE  
 
Prediction Rule for Estimating the Probability of Hospi[INVESTIGATOR_577259] ( Hak et al, 2004) 
Characteristic Scorea 
Age, years 
<70 0 
70-74 14 
75-79 28 
80-89 42 
≥90 56 
Sex 
Female  0 
Male  9 
Outpatient visits during the previous year 
0 0 
1-6 11 
7-12 22 
>[ADDRESS_757510] total score 
Notes: 
a The prognostic score for a given subject can be obtained by [CONTACT_577335]. 
a Pre-existing medical conditions of eligible subjects will be scored following a judgment 
by [CONTACT_093].  
 
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 87 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   APPENDIX 2 – LIST OF ADVERSE EVENTS OF SPECIAL INTEREST 
 
Gastrointestinal disorders  
• Celiac disease  
• Crohn’s disease  
• Ulcerative colitis  
• Ulcerative proctitis 
 
Liver disorders  
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
 
Metabolic diseases  
• Addison’s disease  
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I 
• Grave's or Basedow’s disease  
 
Musculoskeletal disorders  
• Antisynthetase syndrome  
• Dermatomyositis  
• Juvenile chronic arthritis (including Still’s disease)  
• Mixed connective tissue disorder  
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis  
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome  
• Spondyloarthritis, including ankylosing spondylitis, reactive a rthritis (Reiter's Syndrome) and 
undifferentiated spondyloarthritis  
• Systemic lupus erythematosus  
• Systemic sclerosis  
 
Neuroinflammatory disorders  
• Acute disseminated encephalomyelit is, including site-specific v ariants (e.g., non-infectious 
encephalitis, encephalomyelitis, myelitis, radiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (e.g., Bel l’s palsy)  
• Guillain-Barré syndrome, including Miller Fisher syndrome and o ther variants  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 88 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   • Immune-mediated peripheral neuropathies and plexopathies, inclu ding chronic inflammatory 
demyelinating polyneuropathy, multifocal motor neuropathy and p olyneuropathies associated 
with monoclonal gammopathy  
• Multiple sclerosis  
• Narcolepsy  
• Optic neuritis  
• Transverse myelitis  
• Myasthenia gravis, including Eaton-Lambert syndrome  
 
Skin disorders 
• Alopecia areata  
• Autoimmune bullous skin diseases, including pemphigus, pemphigo id and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus  
• Erythema nodosum  
• Morphoea  
• Lichen planus  
• Psoriasis  
• Sweet’s syndrome  
• Vitiligo 
 
Vasculitides  
• Large vessels vasculitis including: giant cell arteritis such a s Takayasu's arteritis and temporal 
arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, Ch urg–Strauss syndrome (allergic 
granulomatous angiitis), Buerger’s disease thromboangiitis obliterans, necrotizing vasculitis and anti-neutrophil cytoplasmic an tibody (ANCA) positive vascul itis (type unspecified), 
Henoch- Schonlein purpura, Behcet's syndrome, leukocytoclastic vasculitis  
 Others  
• Antiphospholipid syndrome  
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glome rulonephritis rapi[INVESTIGATOR_90974], membranous glomerulonephritis, membranoproliferati ve glomerulonephritis, and 
mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia  
• Goodpasture syndrome  
• Idiopathic pulmonary fibrosis  
• Pernicious anemia  
• Raynaud’s phenomenon  
 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 89 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:00                   • Sarcoidosis  
• Sjögren’s syndrome  
• Stevens-Johnson syndrome  
• Uveitis  
ro u 
0 -J 
.... c: ·;:: a.. 
ro ·;; c 
Gl 
:.;::: 
c: 
0 u Protocol Number: V200 I [ADDRESS_757511] Name: [CONTACT_577343] c 
Document Status: Final Version 1.0, Document Date: [ADDRESS_757512] read the protocol entitled "A Phase 2, Randomized, Stratified, Observer -Blind Clinical Study 
to Evaluate Safety and Immunogenic ity of the MF59-Adjuvanted Quadrivalent Inactivated Subunit 
Cell-derived Influenza Vaccine (aQTVc) in adults years of age" and confirm thatto the best of 
my knowledge; the protocol accurately describes the design and conduct of the study. 
Signature: ... ................... Date: 
Name [CONTACT_263335]: (DD MMM YYYY) 
......
Role: ...... ..... . 
.... 
Documen t#: FORMl-000107830, Ed: 1.0 
Source Document#: SOP-000056619 Page 90 of91 

 
Protocol Number: V200_10  
Product Name:  [CONTACT_577340]: Final Version 1.0 , Document Date: 30 Mar 2020  
 
Document #: FORM1-000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 91 of 91 
Effective Date: See System Metadata        Confidential  Print Date (Local): 30-mrt-2020 10:41:[ADDRESS_757513] read the protocol entitled “A Phase 2, Randomized, Strat ified, Observer-Blind Clinical Study 
to Evaluate Safety and Immunogenicity of the MF59-Adjuvanted Qu adrivalent Inactivated Subunit 
Cell-derived Influenza Vaccine (aQIVc) in adults ≥50 years of a ge”, I agree to conduct the clinical 
study, after approval by [CONTACT_577336] (as 
appropriate), in accordance with the protocol, the principles o f the Declaration of Helsinki, the 
standards of Good Clinical Practice (as defined by [CONTACT_577337]) 
and applicable regulatory requirements.  
Changes to the protocol will only be implemented after written approval is received from the 
sponsor and the Institutional Review Board or Independent Ethic s Committee (as appropriate), with 
the exception of medical emergencies.  
I will ensure that the study staff fully understand and follow the protocol.  
 
Signature:  ……………………...………………………  Date:  …………………………  
         (DD MMM YYYY)  
Affiliation and qualifications:  …………………………………………………………………  
Address of Investigator:  …………………………………………………………………  
Electronic Signatures
User Date Justification
30-Mar-2020
12:42:26Manager Approval
